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1.1   Diabetes 
Diabetes Mellitus (DM) was first recognized around 3000 years ago as a disease by the 
ancient Indians and Egyptians, illustrating some clinical characteristics that are now seen in 
diabetes (Frank, 1957). The word diabetes is adopted from the Greek word, ‘siphon’ meaning 
to pass through coined by Araetus of Cappodocia (81-133AD). Later, the Latin word 
‘Mellitus’, meaning ‘honey sweet’ was introduced by Thomas Willis in 1675. By 1776, 
excess sugar in blood and urine was confirmed for the first time by Dobson of Great Britain 
(Ahmed, 2002). With the development of science and technology, the knowledge of diabetes 
and its etiology and pathogenesis became widespread.  
According to the World Health Organization (WHO), “Diabetes is a chronic, metabolic 
disease characterized by elevated levels of blood glucose (or blood sugar), which leads over 
time to serious damage to the heart, blood vessels, eyes, kidneys, and nerves.”   
For our body to function properly, cells require constant supply of energy which is derived 
from the D-glucose obtained from food with the help of a hormone called insulin (Wang & 
Lee, 2015). Insulin is a peptide hormone, synthesized by β-cells of islets of Langerhans 
present in pancreas (Bosco et al., 2010). The size of an insulin molecule is 5.8 kDa 
approximately comprising 51 amino acids and contains two polypeptide chains (A & B) 
which are inter-linked by two disulphide bonds (Mo et al., 2014). Cells cannot absorb glucose 
from blood directly. For this purpose, insulin is synthesized and released from the pancreatic 
β-cells that enables insulin-dependent glucose uptake in our body and hence lowers the blood 
glucose levels and maintains glucose homeostasis (Röder et al., 2016). In those people 
affected by diabetes, pancreas produce insufficient amount of insulin and/or have diminished 
tissue responses to insulin action (American Diabetes Association, 2014; Arnold et al., 2018). 
 1.1.1   Types of diabetes 
Diabetes Mellitus is classified into two major types: type 1 diabetes and type 2 diabetes 
(Canivell & Gomis, 2014). Type 1 diabetes (T1DM) is an auto-immune disorder that is 
characterized by the absolute deficiency of insulin due to the destruction of insulin secreting 
β-cells (Wu et al., 2015). Type 2 diabetes (T2DM) is highly heterogeneous and is 
characterized by insulin resistance, which precedes the onset of the disease condition. Insulin 
resistance followed by progressive decline in insulin secretion is the hallmark of T2DM 
pathogenesis (Tangvarasittichai, 2015). About 75-85% of patients with diabetes are classified 
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as affected by T2DM (Ahlqvist et al., 2018). In addition to T1DM and T2DM there are other 
forms of diabetes: Gestational diabetes mellitus (GDM), is defined as glucose intolerance that 
occurs during second or third trimester of pregnancy (Donazar-Ezcurra et al., 2017); Latent 
autoimmune diabetes in adults (LADA), a hybrid form of diabetes is defined by the presence 
of autoimmune marker glutamic acid decarboxylase antibodies (GADA) similar to T1DM 
patients along with insulin resistance similar to type 2 diabetes (Löfvenborg et al., 2016).  
In addition to these, other atypical monogenic forms of diabetes are as follows: 1) Maturity-
onset diabetes of the young (MODY), is an autosomal dominant inherited monogenic form of 
diabetes (Majidi et al., 2018). Currently, 13 types of MODY are classified (Brunerova et al., 
2018). 2) Neonatal diabetes mellitus (NDM) is a monogenic form of diabetes that is defined 
as diabetes mellitus with onset before six months of age (Thomas & Philipson 2015).           
3) Maternally Inherited Diabetes and Deafness (MIDD) is a monogenic form of diabetes 
caused due to mitochondrial disorder that is characterized by the onset of sensorineural 
hearing loss and diabetes (Naing et al., 2014). 4) Mutant INS-Gene Induced Diabetes of 
Youth (MIDY) (Liu et al., 2010) results from the expression of a mis-folded mutant pro-
insulin protein in pancreatic β-cells.  
1.1.2   Prevalence of Type 2 diabetes and the Indian context 
Type 2 diabetes has now become a major public concern and its increasing prevalence has 
drawn a major public outcry.  It is considered to be one of the most commonly diagnosed 
chronic conditions worldwide following hypertension, arthritis and dyslipidemia (Hsiao et al., 
2010). As per the International Diabetes Federation Atlas 2017 report, around 425 million 
people are diagnosed with diabetes and it is expected to reach 693 million by 2045. A total of 
approximately 72.9 million cases of diabetes were reported in India. India ranks second in the 
world in terms of harbouring a huge population of people with diabetes (IDF, 2017). In an 
ICMR-INDIAB study by Anjana et al. (2017), the cumulative data from 15 Indian states 
suggests the prevalence of diabetes in India to be 7.3% and the prevalence of pre-diabetes to 
be 10.3% of the population. 
1.1.3   Determining criteria for type 2 diabetes 
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According to the International Diabetes Federation (IDF), diabetes is determined by the 
following diagnostic criteria: Fasting plasma glucose concentration >=7mmol/L (126 mg/dL) 
or >=11.1mmol/L (200mg/dL) in 2 hours following a 75g of glucose load.  
Glycated hemoglobin A1c (HbA1c) is a standard marker for measuring long term glucose 
control (Lee, 2015). HbA1c is a measure of an individual’s average blood glucose levels of 
previous two or three months (Sherwani et al., 2016). Hemoglobin is glycated at one or both 
valines in N-terminal of beta chains (Nasir et al., 2010). HbA1c is a measure of beta-N-1-
deoxy fructosyl component of haemoglobin (Miedema, 2005). IDF categorizes diabetes as 
HbA1c ≥ 48 mmol/mol (equivalent to 6.5%).  
Apart from HbA1c, other alternative biomarkers that are in use today for glycemic control 
monitoring are Fructosamine, Glycated Albumin, 1,5-Anhydroglucitol and continuous 
glucose monitoring (Lee, 2015).  
1.1.4   Comorbidities of Insulin resistance 
Diabetes is a complex heterogeneous disease characterized by insulin resistance (Karalliedde 
& Gnudi, 2016). In addition to insulin resistance, the other comorbidities found in T2DM 
patients are hyperglycaemia, inflammation, dyslipidaemia, hypertension, atherosclerosis, 
microvascular complications and renal failure (Arnold et al., 2018). 
1.1.5   Risk factors for type 2 diabetes  
Non-modifiable risk factors 
Age 
Age is a primary risk factor and thus risk of occurrence of T2DM increases with age (Zou et 
al., 2016). However currently, T2DM is also affecting young adults and children (Wu et al., 
2014). 
Race 
People of certain races are more likely to develop type 2 diabetes than others. For example, 
Asians are more susceptible to metabolic diseases at lower BMI when compared to other 
population across the globe (Wen et al., 2009). Body fat composition is higher, and lesser 
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muscle mass is seen in Asian-Indians. These are characteristics of the Asian-Indian 
phenotype.  
Genetic factors 
Inherited genetic susceptibility remains an independent major risk factor for T2DM (Scott et 
al., 2013). Subjects with family history of diabetes i.e., either or both parents or siblings 
affected with the disease, have more chances of acquiring the disease (Murea et al., 2012).  
Modifiable risk factors 
Overweight/Obesity 
There are many modifiable risk factors for T2DM. Being overweight or obese is associated 
with an increased risk for developing insulin resistance and type 2 diabetes (Grover et al., 
2015; Hsu et al., 2015). In obese individuals, adipose tissue undergoes extensive hypertrophy 
and the expansion of the visceral adipose tissue is a strong predictor of the development of 
insulin resistance (Gustafson et al., 2015). In addition to increased fat accumulation, adipose 
tissue releases excessive amount of pro-inflammatory cytokines (Pirola & Ferraz., 2017), 
non-esterified fatty acids (NEFA) (Nemati et al., 2017), and other factors that are involved in 
the genesis of insulin resistance followed by subsequent decline in β-cell function that results 
in the development of type 2 diabetes (Kahn, 2003). According to the WHO, Body Mass 
Index (BMI, calculated as weight in kilograms divided by height in square meter (kg/m2)) 
criteria that determines global obesity is: BMI greater than or equal to 25 is considered to be 
overweight and BMI greater than or equal to 30 is considered to be obese. The BMI range for 
Asian population differs from that of the world population (Gujral et al., 2013). For Asian-
Indian population overweight is defined as a BMI of 23 or higher and BMI of 27 or higher 
falls under obesity (Misra, 2015). Waist Circumference and Waist Hip Ratio are some of the 
important parameters associated with diabetes in Asians (Lear et al., 2007). 
Sedentary life style 
Physical activity helps in utilizing glucose as an energy source more efficiently (Stanford & 
Goodyear., 2014). Endurance exercise training has been shown to enhance the GLUT-4 
expression in skeletal muscles (Higashida et al., 2011; Richter & Hargreaves, 2013). This 
increase in GLUT-4 expression increases the glucose uptake in skeletal muscle (Hussey et al., 
2012; Richter & Hargreaves, 2013).    
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Carbohydrates are the preferred source of energy during intense or moderate exercise. When 
the high intake of carbohydrates is not utilized properly due to physical inactivity, it can lead 
to metabolic diseases like diabetes (Mul et al., 2015). A study by Anjana et al. (2014) in the 
Indian population reported about the prevalence of physical inactivity among large portion of 
the population. This may be one of the reasons for the high prevalence of metabolic disorders 
in the Asian-Indian population (Wells et al., 2016). Association of sedentary behaviour with 
the increased odds of occurrence of T2DM was well documented (Hayes et al., 2002; Van der 
Berg et al., 2016; Engelen et al., 2017). A study by Balkau et al. (2008) which included 801 
healthy individuals, demonstrated that the sedentary time is inversely associated with insulin 
sensitivity. A meta-analysis by Wilmot et al. (2012) examined 10 studies and suggested that 
larger duration of sedentary behaviour has 112% greater relative risk for type 2 diabetes.  
Gestational diabetes  
Several follow up studies have shown that the occurrence of gestational diabetes mellitus 
(GDM) during pregnancy increases the risk of developing T2DM in both mother and child 
later in life (Krishnaveni et al., 2007; Herath et al., 2017). Risk of developing diabetes was 
reported to be 9.6 fold higher in women who had history of GDM (Lee et al., 2007). 
Metabolic alterations such as increase in insulin secretion, increased postprandial free fatty 
acids (FFA), increased hepatic glucose production are witnessed in the women affected by 
GDM which later on results in insulin resistance leading to T2DM (Barbour et al., 2007). 
Hormonal imbalance during the GDM phase in women may also be responsible for 
development of T2DM. For example, 30-fold increase in human placental lactogen (hPL) is 
seen throughout pregnancy of women affected by GDM that induces insulin secretion from 
the pancreas (Brelje et al., 1993). Studies have shown that hPL can cause peripheral insulin 
resistance (Barbour et al., 2007). Epigenetic changes such as histone methylation are 
recorded in women with GDM that can be a potential predictor for occurrence of T2DM in 
the future (Michalczyk et al., 2016). Maternal hyperglycaemic condition tends to bring in 
epigenetic modifications in the offspring genes, resulting in obesity and diabetes in the child 
(Michalczyk et al., 2016).   
Prediabetes 
Prediabetes is a predecessor condition of diabetes where blood sugar level is higher compared 
to normal subjects, but not high enough to be classified as diabetes. If left untreated, a large 
proportion of the individuals with prediabetes may progress to T2DM (Tabák et al., 2012). 
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IDF classifies prediabetes as those having fasting plasma glucose 100–126 mg/dL and/or 2 
hours plasma glucose 140–199 mg/dL after glucose load. 
Metabolic syndrome 
Metabolic syndrome is a complex condition characterized by the presence of a group of 
metabolic risk factors like reduced high-density lipoprotein (HDL), hypertriglyceridemia, 
insulin resistance, dyslipidemia, abdominal obesity, hyperglycemia and hypertension in the 
same individual which cumulatively increases the risk for developing T2DM, cardiovascular 
disease, atherosclerosis, stroke, vascular inflammation, liver, kidney and heart diseases 
(Bonomini et al., 2015; Heindel et al., 2017). 
1.1.6   Type 2 diabetes is a reflection of gene(s) and environment interactions 
Type 2 diabetes is a multifactorial metabolic disease (Nowotny et al., 2015), where 
interactions between genes and environmental factors contribute toward causation of the 
disease (Kaul & Ali, 2016). Though important, genetic factors alone could contribute only 
around 10% for predisposition of diabetes (Herder & Roden, 2011; Billings & Florez, 2011). 
More of environmental influence is seen in the occurrence of the disease. Major hallmarks of 
T2DM like mitochondrial dysfunction, aging, dyslipidemia are the result of combined effects 
of genes and environment (Ling et al., 2009).  
T2DM can be heritable. Evidence support that inherited genetic susceptibility as a risk factor 
for developing T2DM (Murea et al., 2012). Genome-wide association studies (GWAS) have 
identified and reported around 116 genes and 161 SNPs that are linked with T2DM (Cheng et 
al., 2017). Epidemiological evidences from the past suggest that environmental factors play a 
key role in development of diabetes. Individuals who were exposed to famine prenatally in 
The Dutch Hunger Winter Families Study showed impaired glucose tolerance in comparison 
to their unexposed siblings of the same sex (Ravelli et al., 1998; Lumey et al., 2007; 
Heijmans et al., 2008; Tobi et al., 2009). Military personnel who got exposed to dioxins 
during the Vietnam War have shown to be associated with a higher risk of developing 
diabetes (Henriksen et al., 1997). Increased incidence of diabetes was also reported in women 
who were exposed to dioxins during Seveso industrial explosion in Italy (Bertazzi et al., 
2001). 
There are also reports suggesting the association between prenatal environment with the 
incidence of insulin resistance and risk of developing T2DM at later age (Ravelli et al., 1998; 
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Jensen et al., 2002). Rats fed with high-fat diet during pregnancy were shown to deliver 
offspring that developed impaired glucose homeostasis and mitochondrial dysfunctions later 
in life (Armitage et al., 2003; Taylor et al., 2005).   
These studies attest that along with genes, environmental factors play a significant role in the 
genesis of diabetes and its complications. 
1.2   Endocrine Disrupting Chemicals  
The incidence of metabolic complications related to T2DM is highly associated with an 
unhealthy lifestyle such as high calorie diet intake and lack of physical activity (Sami et al., 
2017). In addition to this, a particular group of environmental pollutants defined as Endocrine 
Disruptor Chemicals (EDCs) appear to play a pathophysiological role in the genesis of 
metabolic disorders (Alonso-Magdalena et al., 2011; Fénichel & Chevalier, 2017).  
According to the Endocrine Society, EDCs are defined as “an exogenous [non-natural] 
chemical, or mixture of chemicals, that interferes with any aspect of hormone action.” 
Studies on endocrine disruption began during the famous meeting at the Wingspread 
Conference Center, Racine, Wisconsin in July 1991, organized by Theo Colborn and his 
coworkers (Kabir et al., 2015).  
EDCs are highly heterogeneous exogenous agents (Diamanti-Kandarakis et al., 2009; Polyzos 
et al., 2012) that include synthetic chemicals interfering with synthesis, secretion, transport, 
storage, binding action and elimination of hormones in our body (Mangochi, 2010).  
Plausible intervention of more than 800 compounds with the endocrine system is known but 
only few are well studied (Xin et al., 2015). Some of the widely known EDCs include: 
Polychlorinated biphenyls (PCBs), polybrominated biphenyls, bisphenols, o-phenyl phenols, 
tributyltin (TBT), diethylstilbestrol (DES), dioxins, chlorophenols, phthalates, atrazine, 
triazines, triazoles, triclosan, vinclozin, fluoxetine, alkylbenzene, alkylphenol, persistent 
organic-pollutants (POPs), polybrominated diphenylethers(PBDEs), perfluorooctanesulfonate 
(PFOS), levonorgestrel, hexabromocyclododecane (HBCDD), cyclic methyl siloxanes, 
perfluorooctanoic acid (PFOA), Di(2-ethylhexyl) phthalate (DEHP), Benzo[a]pyrene (BaP), 
4-Nonylphenol, 4-tert-butylphenols, parabens, methyl-mercury and pesticides like 
Dichlorodiphenyltrichloroethane (DDT) derivatives and metabolites (Kabir et al., 2015; 
Maqbool et al., 2016; Darbre, 2017).  
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1.2.1   Sources of EDC 
As shown in Figure 1, most of the EDCs are man-made which has their source from 
pesticides, industrial effluents, plastic industries, pharmaceuticals, rocket propellants, food 
additives, etc. (Neel & Sargis, 2011).  
 
 
Figure 1:  Adopted from Neel and Sargis (2011). Pictorial illustration showing the 
sources and targets of EDCs causing metabolic disorders. Sources of EDC exposure include 
Agriculture wastes to consumer products. Through various routes of exposure, EDC enters 
into the human body and affects metabolic tissues causing metabolic disorders with 
pathophysiological effects such as obesity, insulin resistance, diabetes, hypertension and 
dyslipidemia.  
 
 
 
1.2.2   Endocrine disruptors and metabolic disease 
Several studies across the globe have provided evidences for the links between EDC and 
reproductive and developmental failures (Diamanti-Kandarakis et al., 2009; Main et al., 
2010; Knez, 2013; Costa et al., 2014), cancer (Byford et al., 2002; López-Carrillo et al., 
2010; Hsieh et al., 2011; Khanna et al., 2014), and metabolic diseases like diabetes, obesity 
and metabolic syndrome (Neel & Sargis, 2011; Trasande et al., 2012; Goodman et al., 2014; 
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Lee et al., 2014; Dirinck et al., 2015; Desai et al., 2015; Le Magueresse-Battistoni et al., 
2017). The metabolic target tissues for EDCs include adipose, liver, pancreas, skeletal muscle 
and brain (Neel & Sargis, 2011). 
In the current study, our focus is mainly on bisphenol A which is a major EDC, and its effects 
on pathogenesis of T2DM. 
1.2.3   Bisphenol A and its sources 
Though Bisphenol A (BPA), (2,2-bis(4-hydroxyphenyl)propane) was first synthesized in 
1891 by A.P. Dianin, only during the late 1940s and 1950s, BPA found its usage in plastic 
industry (Rubin, 2011). BPA is a synthetic compound that is used as a raw material in the 
manufacture of polycarbonate plastics and epoxy resins (Brede et al., 2003) and is widely 
applied in daily consumer products (Huang et al., 2018) such as baby toys, infant feeding 
bottles, water pipes, eye glass lens, compact discs, dental sealants, consumer electronics food 
and beverage packaging containers, thermal paper, among many others (Vandenberg et al., 
2007; Fu and Kawamura, 2010; Bernier & Vandenberg, 2017). Figure 2 illustrates possible 
sources of BPA exposure.  
1.2.4   Routes of BPA entry  
Bisphenol A enters the body by oral ingestion, by dermal exposure, or through inhalation. 
Ingestion is considered to be the major route of exposure to BPA in humans (Vandenberg et 
al., 2010). BPA leaches out from polycarbonate plastics, epoxy resins or from other storage 
materials which are in contact with food and water, can enter by oral ingestion through food 
intake or drinking water (Schecter et al., 2010). Non-food source of entry is by dermal 
contact and inhalation. BPA absorption by skin can be through handling of thermal papers or 
products of thermal paper (Zalko et al., 2011; Hormann et al., 2014). Mielke et al. (2011) had 
predicted that dermal exposure of BPA can have a significant contribution to the overall BPA 
exposure in an individual. 
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Figure 2: Representative figure illustrating various source materials for the exposure of 
bisphenol A. The source ranges from cosmetics to medical equipment. Plastic grade numbers 
3 and 7 in the centre indicate PVC plastic and mixture of plastics, respectively, which 
majorly utilize BPA for the manufacturing.      
 
 
There is a possibility of BPA getting released from epoxy-based floorings, adhesives, etc. 
into indoor air and dust. However, exposure through air and dust inhalation is considered to 
be minimal and not an important source of exposure (Dekant and Völkel, 2008; Geens et al., 
2012). 
 
1.2.5   Bisphenol A analogues 
Chemicals with structural or functional similarity to bisphenol A (BPA) are often referred to 
as BPA analogues or derivatives. BPA analogues have been detected in foodstuff (Cacho et 
al., 2012; Liao and Kannan, 2013), thermal paper (Becerra and Odermatt, 2013), river and 
lake sediments near industrialized areas (Liao et al., 2012), and chlorinated and brominated 
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analogues in flame retardants (Voordeckers et al., 2002). Analogues of BPA are also seen in 
human biological specimens (Cobellis et al., 2009; Cobellis et al., 2010; Liao et al., 2012).  
There are totally 31 BPA analogues identified to date (Chen et al., 2016; Pelch et al., 2017; 
Owczarek et al., 2018). They are: 4,4'-(hexafluoroisopropylidene) diphenol (BPAF), 4,4'- 
sulfonyldiphenol (BPS), 4,4'-(1-phenylethylidene)bisphenol (BPAP), 2,2-bis(4-
hydroxyphenyl)butane (BPB), 4,4'-(1,4-phenylenediisopropylidene) bisphenol (BPP), 4,4'-
cyclohexylidenebisphenol(BPZ), Bis(4-hydroxyphenyl)-2,2-dichloroethylene (BPC), BPC-
dichloride,4,4′-Ethylidene bisphenol, 1,1-Bis(4-hydroxyphenyl)ethane (BPE), 4,4'-
dihydroxydiphenylmethane (BPF), 2,2-Bis(4-hydroxy-3-isopropylphenyl) propan (BPG), 
4,4′-(1,3-Phenylenediisopropylidene) bisphenol (BPM), 2,2-Bis(2-hydroxy-5-biphenylyl) 
propane (BPPH), 4,4'-(3,3,5-trimethyl cyclohexane-1,1-diyl) diphenol (BP-TMC), Bisphenol 
A diglycidyl ether (BPA-DGE), 4,4′-(Diphenylmethylene) diphenol (BPBP), 4,4′-
Sulfonylbis[2-(2-propen-1-yl)phenol (TGSA), 4- Hydroxyphenyl 4-isoprooxy phenylsulfone 
(d-8), Phenol, 4,4’-sulfonylbis-polymer with 1,1’-oxybis [2- chloroethane] (d-90), 1,7-bis (4- 
Hydroxyphenylth io)-3,5- dioxaheptane (DD-70), 2,4-Bisphenol S (2,4-BPS), Bisphenol S-
MAE, Bisphenol S-MPE, Methyl bis (4-hydroxyphenyl) acetate (MBHA), 4,4'-bis 
(Ncarbamoyl-4-methylbenzene sulfomide) diphenylmethane (BTUM), Tetramethyl 
Bisphenol A (TMBPA), Bisphenol A bis (diphenyl phosphate) (BDP), 2,4’ Bisphenol F, 
Pergafast 201, Urea urethane compound (UU) and BPA bis (diphenyl phosphate) (BDP), 
4,4′-(9-Fluorenylidene) diphenol (BPFL). 
1.2.6   Structure of BPA and its receptor-binding abilities 
Bisphenol A with chemical formula (CH3)2C(C6H4OH)2, belongs to a group of 
diphenylmethane derivatives with two hydroxyl groups. The structure of BPA is similar to 
endogenous hormone estradiol (E2) (Figure 3), thus possessing estrogenic activity 
(Maruyama et al., 2013). Hence, BPA is known as xenoestrogen (Wang et al., 2017) that 
mimics estradiol activity. BPA has the potential to induce the expression of estrogen 
responsive genes and can promote proliferation of MCF-7 cells similar to estradiol (Wang et 
al., 2018). Previous studies have reported that BPA can act as either agonist or antagonist 
depending on the Estrogen Receptor (ER) subtype and cell type (Kurosawa et al., 2002). BPA 
has a low binding affinity for nuclear estrogen receptors (ERs) α and β, compared to estradiol 
(Kuiper et al., 1998; Wolstenholme et al., 2011; Baker & Chandsawangbhuwana, 2012). 
Interestingly, studies have reported that BPA can act as either agonist or antagonist 
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depending on the Estrogen Receptor (ER) subtype and cell type (Kurosawa et al., 2002; 
Acconcia et al., 2015). 
                                 
        Figure 3A: Structure of Bisphenol A (BPA; 2, 2-Bis (4-hydroxyphenyl) propane) 
                                             
 
                                       Figure 3B: Structure of estradiol [E2]   
   
Figure 3: Illustration showing the structure of Bisphenol A and Estradiol. The chemical 
structures of (A) Bisphenol A (B) Estradiol are presented. The two molecules are structurally 
similar enabling BPA to interact with the estrogen receptors and other estrogen-like receptors 
similar to estrogen action. 
                                  
Estrogen related receptors (ERR-α, ERRβ and ERR-γ), which belong to orphan nuclear 
receptor family have significant homology with ERs (Giguère, 2002; Horard & Vanacker, 
2003). Studies have demonstrated that there was a positive association of higher 
concentration of BPA with higher expression levels of ERβ and ERR-α in peripheral blood 
leukocytes (Melzer et al., 2011; Cipelli et al., 2014). Recent studies had revealed that one of 
the major in vivo receptors for BPA is ERR-γ (Takayanagi et al 2006; Okada et al 2008; 
Tohme et al 2014). Reports have suggested that BPA can bind to thyroid hormone receptor 
and act as an antagonist disrupting thyroid hormone action (Moriyama et al., 2002; Sun et al., 
2009; Delfosse et al., 2014). Molina et al. (2013) through in vitro bioassays demonstrated that 
BPA acts as a strong Androgen Receptor (AR) antagonist. Pereira-Fernandes et al. (2013) 
stated that BPA potentially induces adipogenesis by activating PPARγ. Association of BPA 
with PPARγ is also supported by studies conducted by Riu et al. (2011) demonstrating that 
BPA and its halogenated forms possess the capability of binding to PPARγ. By binding to 
PPARγ, BPA and its halogenated forms are capable of altering early adipogenesis (Somm et 
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al., 2009) and the dysregulation of PPARγ is shown to cause the onset of diabetes and obesity 
(Swedenborg et al., 2009). Studies have also suggested that BPA at low concentrations is 
capable of triggering the effects of G-protein coupled receptor 30 (GPR30) promoting 
cellular proliferation (Bouskine et al., 2009; Chevalier et al., 2012). 
1.2.7   Metabolism and toxicokinetics of BPA 
Acute exposure to BPA has been reported to cause adverse health outcomes in experimental 
animals (Richter et al., 2007); similar findings have also been reported in observational 
epidemiological studies, where BPA exposure was linked to adverse health outcomes 
(Vandenberg et al., 2007).  BPA exposure during fetal development or during postnatal life is 
of utmost concern as the potential of BPA to disrupt normal development is higher because 
the process of metabolizing BPA through conjugation in liver may not be fully developed at 
the early part of life (Gerona et al., 2013; Divakaran et al., 2014). Liver is the major organ 
involved in metabolism of toxic chemicals and substances like BPA (Malaguarnera et al., 
2012).  
Once BPA gets ingested into the body as a free active unconjugated form, the majority of it 
gets quickly conjugated to glucuronide by enzyme Uridine 5'-diphospho-
glucuronosyltransferase (UDP-glucuronosyltransferases) and gets converted to BPA-
glucuronide (BPA-G) (Street et al., 2017). This process is called glucuronidation which is a 
major form of xenobiotic metabolism that occurs in the liver and gut to detoxify and 
eliminate both endogenous compounds and drugs (Dutton, 1980). This conjugated form of 
BPA is more hydrophilic and excreted in urine (Midoro-Horiuti & Terumi, 2017). In humans, 
UGT2B15 is the major isoform of UGT that is responsible for glucuronidation of BPA 
(Hanioka et al 2008). However, other UGTs including UGT1A1, UGT1A3, UGT1A9, 
UGT2B4 and UGT2B7 showed significant levels of glucuronidation activities (Street et al., 
2017). Though a major part of BPA is conjugated to BPA-G, to a lesser extent, unconjugated 
free BPA gets converts into other metabolites, mainly BPA sulphate (BPA-S) through the 
help of cytosolic enzyme sulfotransferase (Gerona et al., 2013; Thayer et al., 2015). The 
conjugated forms of BPA are considered to be biologically inactive as they cannot bind to the 
estrogen receptors. However, recent studies have reported that BPA even in conjugated form 
is capable of evoking cellular response in prolactinoma cells through interaction with ERα 
(Vinas et al., 2013).  
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The half-life of BPA in human body is about 5.4 hours (Ye et al., 2006) and will be 
completely eliminated in 24 hours by renal clearance (Volkel et al., 2002). In the primates, 
the BPA-G is directly eliminated through renal clearance, whereas in rat and mouse, entero-
hepatic circulation of BPA glucuronide results in slow excretory rate (Tominaga et al., 2006). 
Figure 4 illustrates the process of BPA conjugation and excretion. 
 
 
  
Figure 4: Illustration showing the mechanism of BPA conjugation, metabolism and its 
elimination. Unconjugated free active form of BPA is detoxified by conversion into BPA 
Glucuronide (BPA-G) with the help of enzyme Uridine 5’-diphospho-glucuronyl transferase 
(UGT).  Clearance of BPA in primates is in rapid phase and through urine. However, in 
rodents, BPA Glucuronide enters into entero-hepatic circulation that result in slow excretion 
through faeces.  
 
 
 
The interspecies difference in the BPA pharmacokinetics was studied by Collet et al. (2015). 
The study identified that plasma clearance of BPA was high and of same order of magnitude 
as hepatic blood flow across species. BPA clearance in humans is through highly efficient 
hepatic metabolism. However, BPA absorbed through skin and sublingual mucosal 
 16 
 
membrane can directly enter into systemic circulation surpassing liver metabolism (Mielke et 
al., 2011; Patel et al., 2011; Gayrard et al., 2013).  
1.2.8   Bisphenol A- a cause for concern?  
Bisphenol A ingested orally undergoes rapid metabolization in liver followed by excretion 
(Volkel et al., 2002; Thayer et al 2015). However, BPA that enters through skin and oral 
mucosal membrane escapes liver metabolism (Gayrard et al., 2013) and is metabolised with 
lower efficiency compared to liver metabolism (Gundert-Remy et al., 2014; Toner et al., 
2018). This increases the overall bioavailability of BPA in circulation. BPA even in 
conjugated form is reported to cause adverse effects. Boucher et al. (2015) demonstrated that 
conjugated form of BPA i.e., BPA-G, when treated to primary human pre-adipocytes, 
induced adipogenesis, which indicates that BPA-G is not an inactive metabolite as previously 
thought. Further research in this direction is needed. In addition, deconjugation of BPA from 
BPA-G and BPA-S to free form was also reported in foetus (Corbel et al., 2015; Gauderat et 
al., 2016). Possibility of this process in adults has to be researched further.  
Toxicology studies have established no-observed-adverse-effect-level (NOAEL) dose for 
BPA ranging from 5 to 50 mg/kg/day (Draganov et al., 2015). Continuous exposure to BPA 
through various sources is inevitable (Vandenberg et al., 2009). Effect of BPA depends on 
many factors such as gender, dose and timing of exposure. Effects due to the exposure of 
BPA during gestation or on foetus is considered to be the most severe, compared to other 
timing of exposure (Liu et al., 2013).  
1.2.9   Bisphenol A exposure levels across population                                         
Bisphenol A was a subject of concern as early as 1960. Gaul (1960), first reported a case 
where a young man developed allergic reaction to epoxy resin containing BPA. However, 
there was not much concrete evidence to report that BPA causing such allergic reactions. 
Currently, large body of evidences point towards the links between BPA and adverse health 
outcomes detected in humans, animals and in in vitro models (Vom Saal et al., 2007; Richter 
et al., 2007). Several studies have determined the levels of BPA in human serum and urine 
across the globe confirming that BPA is ubiquitous, and humans are subjected to wide spread 
exposure of BPA (Vandenberg et al., 2010; Rochester, 2013). 
 17 
 
Oral intake of BPA was reported to be the main source of BPA entry into humans (Kang et 
al., 2006). Lorber et al. (2015) determined the daily BPA intake through canned food to be 
12.6 ng/kg-day in adult U.S. population that was then compared with National Health and 
Nutrition Examination Survey (NHANES) reports from 2005 to 2010 that determined the 
BPA intake to be between 30 ng/kg-day and 70 ng/kg-day. The difference in estimation was 
explained as due to the fact that possibilities of exposure to BPA from non-canned food and 
also from other non-dietary sources such as dermal entry from thermal papers, dust and air 
borne exposures (Lorber et al., 2015).  
The European Food Safety Authority, based on previous studies, has reported the exposure 
levels of BPA according to age group of the population. Average dietary exposure of BPA in 
infants aged 0-6 months was 30 ng/kg/day; in toddlers aged 1-3 years was 375 ng/kg/day; in 
children aged 3-10 years was 290 ng/kg/day; in adolescents aged 10-18 years was 159 
ng/kg/day; in adults aged 18-45 year was 132 ng/kg/day; in adults aged 45-65 year was 126 
ng/kg/day; and in elderly aged 65 above was 116 ng/kg/day. Among non-dietary exposure 
category, thermal paper exposure through skin had the highest average of 94 ng/kg/day in 
adolescents (aged 10-18 years). Other major source and routes of exposure estimated include 
cosmetics (dermal), dust (oral/ingestion), toys (oral/ingestion) and air (inhalation) (Ćwiek-
Ludwicka, 2015).    
Teeguarden et al. (2013) determined human serum BPA concentration using various BPA 
exposure estimates and human biomonitoring data. The result estimated the serum BPA 
concentrations to be between 0.003 pM and 290 pM. Apart from urine and serum, BPA was 
also detected in different body fluids, such as milk (Sun et al., 2004; Migeot et al., 2013; 
Mendonca et al., 2014; Altamirano et al., 2015; Niu et al., 2017; Lee et al., 2018; 
Mercogliano & Santonicola, 2018), maternal urine (Callan et al., 2013; Ferguson et al., 
2015), amniotic and placental fluids (Ikezuki et al., 2002; Schönfelder et al., 2002; Shekhar et 
al., 2017; Lee et al., 2018) and saliva (Sasaki et al., 2005; Zimmerman-Downs et al., 2010; 
Berge et al., 2017).   
In Indian population, very few studies have analyzed the levels of BPA. Zhang et al. (2011) 
determined the total urinary BPA concentration from samples collected from seven Asian 
countries: China, India, Japan, Korea, Kuwait, Malaysia, and Vietnam. The geometric mean 
concentration of BPA levels was 2.7 pM, and India accounted for 3.84 pM. Xue et al. (2015) 
measured the urinary levels of endocrine disruptor chemicals including BPA in obese and 
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non-obese Indian children. The study reported geometric mean and SD of BPA levels as 
11.41 pM and concluded that there was no association between BPA and obesity. Apart from 
these studies, there was not much of detailed analysis of BPA levels in the Indian population; 
and especially no data on BPA levels in the diabetes clinical setting.  
Evidences from various studies have associated BPA with developmental disorders, 
reproductive failure and cancer. A brief account on the link between BPA and these disorders 
are summarized below.  
1.2.10   Effects of BPA on development 
The concept of “the fragile foetus” was proposed by an epidemiologist, Howard Burn, in the 
early 1970s and confirmed by a series of experiments exposing mouse embryos to BPA. It 
has been shown that active unconjugated form of BPA can surpass placental barriers and 
reach the foetus (Balakrishnan et al., 2010; Mørck et al., 2010), which has the potential to 
affect the unborn. Epidemiological studies have shown the detrimental effects of BPA 
exposure during gestation and development. Recurrent miscarriages (Sugiura et al., 2005) and 
premature delivery (Cantonwine et al., 2010) were associated with exposure to BPA during 
gestation. Snijder et al. (2013) suggested that BPA exposure during gestation may impair the 
foetal development. In utero exposure to BPA can affect birth weight of the offspring (Miao 
et al., 2011; Chou et al., 2011; Philippat et al., 2012). Recent findings from Pinney et al. 
(2017) also reported that BPA concentration in amniotic fluid was associated with reduced 
birth weight in infants. Conversely, a recent meta-analysis by Hu et al. (2018) did not find 
any association between BPA exposure during gestation and lower birth weight.   
In vivo experiments in animal models have demonstrated the effects of BPA on 
embryogenesis. Pastva et al. (2001) reported transient embryonic deformities in medaka 
(Japanese rice fish) when it was exposed to environmentally relevant concentrations of BPA. 
Experiments of Ramos et al. (2003) demonstrated that male rats when prenatally exposed to 
environmental doses of BPA can induce both transient and permanent changes in male 
reproductive axis. Duan et al. (2008) reported that high dose exposure of BPA during 
embryogenesis of zebrafish resulted in mortality while sub-lethal dose resulted in cardiac 
edema and tail malformation. Tse et al. (2013) showed that exposure to BPA during early 
stages of embryogenesis, affected segmentation, dorsoventral patterning and brain 
development in zebrafish. Gibert et al. (2011) demonstrated that exposure to BPA during 
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early embryogenesis of zebrafish resulted in malformation of otolith. Head malformation was 
also noted in Xenopus laevis embryos when they were exposed to BPA (Imaoka et al., 2007).  
1.2.11   Effects of BPA on reproduction 
Several epidemiological studies have linked BPA with infertility both in men and women. 
Studies have observed that the increase in urinary BPA levels was significantly associated 
with decreased libido and sexual desire, difficulty in erection and lower ejaculation rate (Li et 
al., 2010), low sperm count, sperm concentration, sperm vitality, sperm motility, increased 
DNA damage in sperms (Meeker et al., 2010; Li et al., 2011) and may influence human 
steroidogenesis (Vitku et al., 2016). A cross-sectional study by Liu et al. (2015) on Chinese 
men associated the increased BPA exposure to significantly increased estradiol, prolactin, 
and sex hormone binding globulin levels in male and concluded that it may contribute to 
male infertility. Studies have also reported that BPA exposure may increase the risk for 
developing cryptorchidism (Komarowska et al., 2015). Studies have found significant 
association between higher levels of BPA exposure in women with Polycystic Ovarian 
Syndrome (PCOS) (Takeuchi et al., 2004; Kandaraki et al., 2011; Tarantino et al., 2013). 
Some studies have stated that BPA exposure may influence the oocyte quality and fertility 
rates during in vitro fertilization (IVF) (Fujimoto et al., 2010; Ehrlich et al., 2012). 
Experiments in in vivo model organisms have also given enormous evidence for adverse 
effects of BPA on reproduction. BPA exposure during gestational period is reported to 
develop adverse effects on reproductive capacity in both male and female animals. A study 
by Salian et al. (2009) on rats demonstrated that the mothers who were exposed to BPA 
during their gestation and lactation, gave birth to infertile male offspring. In utero exposure to 
BPA was shown to affect reproductive function for several generations in female mice (Ziv-
Gal et al., 2015). Perinatal exposure to BPA was reported to affect folliculogenesis and 
steroidogenesis in female rats (Santamaría et al., 2016). An experiment on rhesus monkey by 
Hunt et al. (2012) demonstrated that BPA alters oogenesis and follicle formation. Reports 
have suggested that neonatal exposure to BPA may affect the reproductive potential of 
animals later in life (Aikawa et al., 2004; Adewale et al., 2009) and may also lead to poly 
cystic ovarian syndrome in female animals (Fernández et al., 2010). Gurmeet et al. (2014) 
reported that BPA is harmful to male reproductive system even at doses that are lower than 
NOAEL (no observed adverse effect levels) dose. D’Cruz et al. (2012) found that BPA 
exposure even at low doses could decrease GLUT-8 expression in spermatocytes of rat and 
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can impair testicular function by disturbing glucose homeostasis. Experiments in male rats by 
Tiwari and Vanage (2013) reported that BPA may act as weak germ cell mutagen and can 
cause DNA damage in sperm. Male Sprague-Dawley rats which were exposed to BPA 
developed lesions in Sertoli and Leydig cells (Jiang et al., 2016). Studies performed with rat 
and goat sertoli cells demonstrate that BPA may decrease the vitality of sertoli cells and thus 
induce apoptosis (Iida et al., 2003; Qi et al., 2014; Wang et al., 2015; Zhag et al., 2017). 
Wang et al. (2017) reported that BPA induces excess generation of reactive oxygen species 
(ROS) and mitochondrial dysfunction in sertoli cells and thereby leads to apoptosis. 
1.2.12   BPA and carcinogenesis 
Occurrence and prevalence of cancer of endocrine target organs such as breast, prostate and 
testis are increasing. Endocrine disruptors like BPA have been reported to contribute to this 
increasing trend of cancers (Seachrist et al., 2015). Exposure to BPA showed the enhanced 
susceptibility for occurrence of cancer, as it is capable of initiating pro-inflammatory markers 
(Savastano et al., 2015) and other genes associated with cancer (Hussain et al., 2015) and 
capable of altering epigenomics during development and promotes the cancer development 
with aging (Ho et al., 2006). BPA is reported to induce transition and stimulates migration of 
cancer cells (Recchia et al., 2004; Kim et al., 2015). The first clinical evidence for association 
of BPA with prostate cancer was reported by Tarapore et al. (2014). The study reported that 
the urinary BPA levels were higher in patients with prostate cancer than those without. BPA 
is reported to act as mammary gland carcinogen. Sprague et al. (2013) reported that increased 
serum BPA levels in postmenopausal women correlated with mammographic breast tissue 
density. Reports have also indicated that occupational exposure to BPA may increase the 
incidence of breast cancer (DeMatteo et al., 2012). An animal study suggests that, rat exposed 
to BPA during developmental stages may induce mammary gland neoplasms (Jenkins et al., 
2009; Acevedo et al., 2013) and can increase the secretion of progesterone and cell number, 
making it susceptible to develop breast cancer (Ayyanan et al., 2011).  
1.2.13   BPA and metabolic disorders 
Incidence and progression of metabolic anomalies like metabolic syndrome, obesity and   
diabetes are steadily increasing worldwide. Lifestyle factors such as lack of physical activity, 
high calorie diets, and genetic predisposition are the causes for the raise of these metabolic 
disorders. Recent evidences suggest that along with other factors, endocrine disruptor 
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chemicals (EDC) may play a key role in initiation and progression of metabolic disorders 
(Newbold et al., 2009; Chevalier & Fénichel, 2016). Among them, BPA is one of the major 
EDCs that is increasingly studied worldwide for its role in metabolic abnormalities. The 
potential role of BPA in initiation and progression of metabolic disorders had been 
investigated in some epidemiological and animal studies (Lang et al., 2008; Alonso-
Magdalena et al., 2010). Several studies have suggested an association of urinary BPA levels 
with insulin resistance and obesity (Carwile & Michels, 2011; Wang et al., 2012; Trasande et 
al., 2012; Oppeneer & Robien, 2015).  
1.3   BPA and type 2 diabetes 
Findings of various studies that reported an association between BPA and T2DM, and tissue 
specific effects of BPA are discussed in the following sections. 
1.3.1   Epidemiological studies in Humans 
BPA has been shown to be associated with T2DM in many epidemiological studies. 
However, some studies have also reported no association.  
A number of cross-sectional studies on BPA had used dataset from National Health and 
Nutrition Examination Survey (NHANES). The first among them was conducted by Lang et 
al. (2008) who used NHANES data from 2003-04 and reported an association between higher 
urinary BPA levels and diabetes. Subsequent study by Melzer et al. (2010) that used data 
from 2005-06 did not find any association and reported lower levels of BPA compared to 
2003-04 data. However, a pooled data from 2003-08 by Shankar and Teppala (2011) reported 
an association between BPA and T2DM. Association between BPA and metabolic syndrome 
(Teppala et al., 2012), and association between BPA and prediabetes (Sabanayagam et al., 
2012) was also reported by the same group. Beydoun et al. (2014) also used NHANES data to 
report an association between BPA levels with increased insulin resistance in men. A similar 
kind of study from Canada showed that urinary BPA levels were associated with diabetes and 
increased glycemic parameters such as HbA1c and blood glucose levels (Tai & Chen, 2016). 
A study from Thai population reported higher levels of BPA in patients with diabetes 
(Aekplakorn et al., 2009). The study concluded by stating that, the association found was 
stronger in men compared to women. A recent study from the same Thai population, noted an 
association between BPA and impaired fasting glucose (Chailurkit et al., 2017). However, the 
study did not find any significant association between BPA and diabetes. A longitudinal 
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study by Sun et al. (2014), reported the association between urinary levels of BPA and the 
risk of developing T2DM in middle aged women. However, the study could not find any 
relation between BPA levels and risk of developing T2DM in older women.   
Similar studies across the globe have reported significant association between BPA and 
diabetes (Wang et al., 2012; Mouneimne et al., 2017) or risk of developing diabetes 
(Ahmadkhaniha et al., 2014), and also BPA levels linked to insulin resistance (Lee et al., 
2013; Khalil et al., 2014; Menale et al., 2017) and other comorbidities of diabetes such as 
high glucose level and inflammation (Savastano et al., 2015; Choi et al., 2017). Conversely, a 
few recent studies did not find any association between BPA levels and T2DM. A recent 
follow-up study from China reported no association between BPA level and T2DM (Shu et 
al., 2018). A Danish study in children reported opposite associations as well. A Study by 
Carlsson et al. (2018) reported an association between higher BPA levels and lower insulin 
resistance. Despite the fact that Indians are highly prone to insulin resistance, diabetes and 
cardiovascular diseases (Shah & Mohan, 2015), there is lack of data on BPA in the clinical 
setting. 
1.3.2   Animal studies 
Most of the studies involving gestational exposure of BPA have reported to have adverse 
effects on male offspring. Gestational exposure of mice to low doses of BPA resulted in male 
offspring with glucose intolerance and mild disruption to β-cell function (Alonso-Magdalena 
et al., 2010). Angle et al. (2013) have reported that BPA exposure during gestation and 
lactation led to increased postnatal body weight in male mice which was accompanied by 
increased liver weight, changes in adipocyte number and volume of abdominal fat and 
glucose intolerance. Liu et al. (2013) also demonstrated that perinatal exposure to BPA led to 
development of glucose intolerance in male mice. García-Arevalo et al. (2014) demonstrated 
that exposure to BPA during pregnancy disrupted glucose homeostasis and β-cell function in 
male mice which mimic T2DM in humans. Studies have additionally shown that BPA when 
combined with metabolic stressor such as high-fat diet (HFD), aggravated the underlying 
metabolic disorder. A study by Wei et al. (2011) exposed rats to BPA during gestation and 
lactation, with the pups later placed on either normal or HFD. The results showed that BPA 
was able to induce glucose intolerance, increase body weight and insulin levels in male 
offspring. These effects were aggravated in male offspring that were given a HFD which 
resulted in enhanced obesity, dyslipidemia, glucose intolerance, and structural damages to 
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pancreatic β-cells. Interestingly, another study by Susiarjo et al. (2015) have reported that 
early life exposure to BPA can disrupt metabolic health across multiple generations – 
particularly in the male offspring – through stable inheritance of DNA methylation changes 
resulting in higher body fat and perturbed glucose homeostasis. 
Exposure to low doses of BPA for 4 days, increased insulin resistance and glucose 
intolerance and reduced β-cell function in adult mice (Alonso-Magdalena et al., 2006; Ropero 
et al., 2008). Studies with 8 days of exposure to BPA have reported the occurrence of insulin 
resistance (Batista et al., 2012). Long-term exposure experiment in mice was reported to 
develop hyperglycaemia and hypercholesterolemia (Marmugi et al., 2014; Moghaddam et al., 
2015). A recent study by Veissi et al. (2018) on male mice showed that BPA exposure 
disrupts glucose homeostasis and elevates glucose levels by reducing insulin secretion and β-
cell function. Several other experiments on different animals such as mice (Moon et al., 
2015), rat (Mullainadhan et al., 2017; Song et al., 2014), rabbit (Fang et al., 2015) and 
zebrafish (Zhao et al., 2018) have demonstrated that BPA exposure may disrupt glucose 
homeostasis and induce hyperglycaemia and insulin resistance.  
1.4   Effect of BPA on metabolically active target tissues 
Several studies have demonstrated the potential of BPA to impair glucose metabolism by 
targeting metabolic tissues viz., liver, pancreas, adipose tissue, skeletal muscles and central 
nervous system. 
1.4.1   Potential effects of Bisphenol A on Liver 
The energy demand in our body is met by glucose homeostasis that is controlled by the liver 
through various metabolic pathways that includes glycogenolysis (break down of glycogen), 
glycogenesis (formation of glycogen), glycolysis (break down of glucose) and 
gluconeogenesis (generation of glucose from non-carbohydrate substrates) (Han et al., 2016).  
In addition to these, liver plays a major role in detoxifying chemical/toxic substances, drugs 
and environmental contaminants. BPA as an environmental contaminant gets metabolized in 
the liver (Malaguarnera et al., 2012). Several studies have reported that BPA exposure may 
induce liver damage in animals (Yıldız & Barlas, 2013; Avci et al., 2016; Thoene et al., 
2017). Experiments of Hassan et al. (2012) with rat model demonstrated that BPA induces 
hepatotoxicity by creating oxidative stress. Jayashree et al. (2013) reported that, adult male 
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albino rats when exposed to BPA showed reduction in hepatic glucose oxidation together 
with reduced insulin receptor expression and reduced glycogen production. This shows that 
BPA has the potential to disrupt hepatic glucose oxidation and reduces glycogenesis. 
Naville et al. (2013) demonstrated that, even at low doses, BPA can induce hepatic metabolic 
dysfunction. A study conducted by Xia et al. (2014) in rat offspring demonstrated that 
perinatal exposure of BPA leads to mitochondria mediated apoptosis in liver. The study also 
found that mitochondrial activities like ATP synthesis, MRC (mitochondrial respiratory 
chain) activity and mitochondrial membrane potential were progressively reduced in 
offspring exposed to BPA leading to the development of hepatic steatosis later in life. A 
study by Marmugi et al. (2014) analyzed expression levels of genes that are involved in 
hepatic carbohydrate metabolism in adult male CD1 mice after exposing it to BPA with doses 
below No Observed Adverse Effect Level (NOAEL). The results showed a marked increase 
in the expression of glucokinase (Gck) and pyruvate kinase (L-Pk) genes that are involved in 
glycolysis. Also, the study showed over expression of genes involved in biogenesis of 
cholesterol. This shows that BPA by altering gene expression signature affects glycolysis and 
cholesterol biogenesis leading to hyperglycaemia and hypercholesterolemia even at low 
doses. Several studies have also reported the potential effect of BPA to induce epigenetic 
alteration in liver resulting in metabolic dysfunction. Ma et al. (2013) reported abnormal 
DNA methylation in rats exposed to BPA during gestation. The study reported an increase in 
promotor hypermethylation and reduction in gene expression of hepatic glucokinase resulting 
in insulin resistance and impaired glucose tolerance in adulthood. Another study showed that 
long-term exposure of mice to BPA can induce hepatic lipid accumulation through epigenetic 
reprogramming of genes involved in lipid metabolism (Ke et al., 2016). 
1.4.2   Potential effects of Bisphenol A on Pancreatic β-cells 
Pancreas produces two major hormones- insulin and glucagon, which play a pivotal role in 
the regulation of glucose homeostasis (Jouvet & Estall, 2017). While glucagon is produced in 
α-cells, insulin is produced in β-cells of pancreatic islets. Any dysregulation to pancreatic 
function can affect production of insulin and glucagon that further affects glucose 
homeostasis leading to metabolic disorders like insulin resistance and T2DM (McGarry, 
2001). Estrogen is known to regulate pancreatic function through activating estrogen 
receptors that are expressed in pancreatic cells that aids in insulin secretion and sensitivity 
and proper β-cell function (Nadal et al., 2009).  BPA as a xenoestrogen, can mimic estradiol 
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(a form of estrogen) in pancreas and lead to over-production of insulin through ERα by 
activating ERK1/2 pathway (Alonso-Magdalena et al., 2006, 2008). In vitro studies by 
Adachi et al. (2005), showed the potential of BPA to release insulin in response to glucose 
when rat islets were treated with BPA for 24 hours 10 µg/L. In another in vitro study. Makaji 
et al. (2011) examined the effect of six environmental contaminants on pancreatic β-cell 
function. Among them, only BPA at concentration of 100 ng/mL, affected the insulin 
secretion and long-term exposure to BPA resulted in endoplasmic reticulum (ER) stress in the 
β-cells. ER stress is one of the important contributors to the pathogenesis of T2DM (Back et 
al., 2012). Lin et al. (2013) studied the effect of BPA on insulin secretion in vitro using INS-1 
cells. The study showed that exposure to higher BPA concentration of 0.20 or 2.0 µM 
resulted in reduction in Glut 2 and GCK gene expression. BPA exposure also resulted in 
apoptosis, which leads to mitochondrial defects that, in turn, resulted in the decline of 
glucose-stimulated insulin secretion. In vivo studies on mice have also revealed that BPA 
even at low doses starting from 10μg/kg/day, has the capacity of disrupting pancreatic β-cell 
function and resulting in insulin resistance in male mice (Alonso-Magdalena et al., 2006). 
1.4.3   Potential effects of Bisphenol A on Adipose tissue 
White adipose tissue is an endocrine tissue that secrets adiponectin and leptin which are 
involved in energy metabolism and homeostasis (Coelho et al., 2013). Leptin mainly acts on 
the central nervous system, specifically hypothalamus and helps in regulating energy intake 
and fat deposition uptake (Gao & Horvath, 2008). Adiponectin plays a major role in 
regulating glucose (Ben-Jonathan et al., 2009). Xenoestrogens like BPA can control 
adipogenesis and its function (Newbold et al., 2005; Hugo et al., 2008). Using 3T3-L1 
adipocytes, Ariemma et al. (2016) reported that BPA exposure at low doses during 
adipogenesis can lead to metabolic dysfunction. Several in vivo and in vitro studies have 
showed that BPA is capable of modulating expression patterns of several genes related to 
adipocyte differentiation and function, which may result in metabolic dysfunction and obesity 
(Somm et al., 2009; Linehan et al., 2012; Ohlstein et al., 2014; Song et al., 2014). Valentino 
et al. (2013) through their in vitro study in human adipocytes observed that BPA at low doses 
diminishes insulin dependent glucose utilization and up-regulates inflammatory pathways. 
Sakurai et al. (2004) reported that BPA is capable of altering the expression of glucose 
transporter (GLUT4) and thereby affecting the glucose uptake by adipocytes. Angle et al. 
(2013) investigated the perinatal effects of BPA exposure in male mice. The study found an 
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increase in body weight and abdominal fat. In addition, the study also found higher levels of 
insulin and leptin in the blood with an associated reduction in serum adiponectin levels. 
These results indicate that BPA exposure can disrupt adipogenesis and cause metabolic 
dysfunction in adipose tissues.  
1.4.4   Potential effects of Bisphenol A on Neuroendocrine system 
Only in recent years, effects of BPA exposure on the central nervous system got attention, as 
studies are reporting that BPA can accumulate in several regions of brain. An in vivo study by 
Mita et al. (2012) on Balb-C mice offspring revealed that, based on gender and dose, BPA 
can accumulate in the brain. The study failed to report any subsequent phenotypic changes 
associated with it. A study by Elsworth et al. (2013) in non-human primates revealed that 
prenatal BPA exposure may decrease synaptogenesis and hippocampal spine synapses and 
impact the formation of mid brain dopamine neurons.  
The central nervous system regulates energy expenditure and feeding behaviour through 
hypothalamus, and studies have revealed the impact of BPA exposure on hypothalamus. 
Experiments in Zebrafish embryos by Kinch et al. (2015) showed that low dose exposure to 
both BPA and its analogue BPS (Bisphenol S) induces premature hypothalamic neurogenesis.  
Hypothalamic estrogen receptors: estrogen receptor α (ERα/ESR1) expression is crucial in 
regulating food intake, body fat distribution, energy expenditure (Frank et al., 2014); and 
postnatal sex-specific expression of estrogen receptor (ERβ/ESR2) is vital in brain for socio-
sexual behaviour (Cao et al., 2014). Rebuli et al. (2014) studied the effects of low dose oral 
exposure to BPA on estrogen receptors expression in hypothalamus of juvenile and adult 
female rats. The result suggested that BPA reduces ESR1 expression levels in juvenile female 
rats and reduced ESR2 expression levels in adult female rats. 
1.4.5   Potential effects of Bisphenol A on skeletal muscle 
Skeletal muscles are an important metabolic tissue that plays a role in maintaining proper 
glucose metabolism. It is the primary insulin-sensitive tissue in the body that induces insulin-
stimulated glucose uptake (Stump et al., 2006). This process is carried out with the help of 
glucose transporter-4 (GLUT-4), which translocates into the plasma membrane through the 
intracellular signalling mechanism involving insulin receptors and Akt (Protein kinase B) that 
facilitates the glucose uptake (Saltiel & Kahn, 2001; Satoh, 2014). For maintaining proper 
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blood glucose levels in circulation, insulin promotes glucose utilization in muscle cells, thus 
inhibiting hepatic gluconeogenesis (Fritsche et al., 2008).  
A study by Indumathi et al. (2013) in male rats reported that BPA exposure resulted in the 
reduction in the levels of insulin receptors, Akt, Akt phosphorylation and GLUT-4. 
Mullainadhan et al. (2017) have also reported similar results. The study demonstrated that 
BPA exposure in male rats, reduced protein expression levels of Insulin receptor (IR), Insulin 
receptor substrate (IRS-1) and reduced Akt phosphorylation along with dysregulation of 
GLUT-4 translocation that was achieved by altering SNARE protein that is required for 
GLUT-4 translocation. These data suggest that BPA by disrupting glucose homeostasis in 
skeletal muscle can lead to insulin resistance.  
1.5   Cellular Senescence  
Cellular senescence is an irreversible process where the damaged cells are permanently 
arrested from replication in G1/G0 phase of cell cycle as a result of different types of 
damaging stimuli (Muñoz-Espín & Serrano, 2014) like external stress signals, DNA damage 
or oncogene activity (Lee et al., 2015; Ben-Porath et al., 2005; Lloyd, 2002; Serrano et al., 
2001). This phenomenon for the first time was described by Hayflick as he observed 
senescent cells in serially passaged human fibroblast cell culture (Hayflick and Moorhead, 
1961). Figure 5 illustrates cell cycle check points and effect of senescence stimuli leading to 
cellular senescence. Senescence majorly occurs in aged organisms where it contributes to the 
decline of tissue function, promoting inflammation and cell cycle arrest (López-Otín et al., 
2013); it is also seen during embryogenesis where it helps in remodelling tissues (Hernandez-
Segura et al., 2018).  
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Figure 5: Illustration of cell cycle check points and effect of senescence stimuli. External 
stimuli such as stress, oncogene activation, DNA damage are capable of inducing p16 and/or 
p53 pathways leading to inhibition of cyclin dependent kinases resulting in cell cycle arrest 
and cellular senescence.  
 
1.5.1   Types of cellular senescence 
Cellular senescence is of different types based on the sources of induction: Oncogene-
induced senescence, Replicative senescence, Stress-induced premature senescence, DNA 
damage-induced senescence, mitochondrial dysfunction-associated senescence, 
epigenetically induced senescence, Chemotherapy-induced senescence and Paracrine 
senescence (Hernandez-Segura et al., 2018).  
Oncogene-induced senescence 
Activation of oncogenes such as BRAF or RAS and/or inactivation of tumor suppressor 
genes like PTEN can lead to oncogene-induced senescence (Muñoz-Espín & Serrano, 2014; 
Sharpless & Sherr, 2015).  
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Replicative senescence 
Replicative senescence refers to the arrest of proliferative potential of the cells after multiple 
cell cycle divisions (Druelle et al., 2016). Telomere shortening is observed and noted as a 
cause for this type of senescence (Sharpless & Sherr, 2015).  
Telomere shortening and DNA-damage-induced senescence 
Irrepairable damage to the DNA or telomere attrition may trigger DNA-damage response 
(DDR). DDR involves secretion of DNA damage kinases such as ATR, ATM, CHK1 and 
CHK2 which further induces the phosphorylation of p53 which in turn transactivates the 
expression of p21, which inhibits CDK–cyclin complexes leading to senescence (Muñoz-
Espín & Serrano, 2014).  
Mitochondrial dysfunction-associated senescence (MiDAS) 
Wiley et al. (2016) have reported that mitochondrial dysfunction can induce senescence, 
which has a characteristic of distinct MiDAS associated secretary phenotype.  
Stress Induced Premature Senescence (SIPS) 
Senescence that occurs as a result of induction by exogenous chemicals, oxidizing agents 
(also known as oxidative stress-induced senescence), ionizing radiation or by DNA damaging 
agents. SIPS show similarities in mechanism with Replicative senescence (Rajarajacholan & 
Riabowol, 2015; Hernandez-Segura et al., 2018).   
Epigenetically induced senescence 
Histone deacetylase such as sodium butyrate and suberoylanilide hydroxamic or DNA 
methylase inhibitors such as 5-azacytidine and 5-aza-2'-deoxycytidine are known to induce 
senescence (Venturelli et al., 2013; Petrova et al., 2016; Sidler et al., 2017). 
Chemotherapy-induced senescence 
Anticancer drugs such as doxorubicin, bleomycin, abemaciclib or palbociclib are capable of 
inducing senescence mechanism either through DNA damage or by cyclin dependent kinase 
inhibition (Petrova et al., 2016). 
Paracrine senescence 
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Paracrine senescence is the induction of senescence in neighbouring cells by a primary 
senescent cell in a paracrine manner that is achieved by producing senescence-associated 
secretory phenotype (SASP) (Acosta et al., 2013).  
1.5.2   Biomarkers to identify cellular senescence 
While cellular senescence can be triggered by a wide range of conditions, the senescent cells 
display a number of morphological characteristics that allow their identification. Cells 
undergoing senescence tend to display morphological changes like enlargement and 
extension, vacuolizing, and becoming multinucleated (Kuilman et al., 2010).  
Some of the biomarkers, separately or in combination, are widely accepted to define 
senescence in both cell culture and in tissues (Collado & Serrano, 2006). Expression of 
markers that are mediators of senescence or cell cycle arrest include: p15, p16, p14ARF, p53, 
p21, p27 and retinoblastoma (RB) (hypophosphorylated) (Muñoz-Espín & Serrano, 2014). 
Absence of proliferative markers, nuclear aberrations and activation of tumor suppressor 
networks are also considered to be biomarkers that are indicative of cellular senescence 
(Görg et al., 2015).  The most widely accepted and used biomarker for detection of cells 
undergoing senescence is β-galactosidase assay. It is the histochemical detection 
of β-galactosidase activity at pH 6.0 and this assay is also known as senescence-associated β-
galactosidase (SA-β-GAL) (Dimri et al., 1995). Senescent cells show increased lysosomal 
content, which enables the detection of enzyme lysosomal β-galactosidase at pH 6.0 (Kurz et 
al., 2000). The increased lysosomal content also reflects on autophagy that occurs in 
senescent cells. The major limitation of this assay is that it needs fresh samples to detect 
senescence. In addition to this, Sudan Black B is also used to stain senescent cells positively 
and can also be used in paraffin-embedded tissues. It detects the lysosomal aggregate known 
as lipofuscin in the cells (Georgakopoulou et al., 2013).  
In addition to these biomarkers, senescent cells secrete a number of extracellular factors such 
as insulin-like growth factor 1 (IGF1) -binding proteins, plasminogen activator inhibitor 1 
(PAi-1), transforming growth factor-β (TGFβ), inflammatory cytokines and chemokines that 
help in pathogenesis of senescence process in an autocrine and paracrine manner (Kuilman & 
Peeper, 2009; Acosta et al., 2013). Other markers present in cells that undergo senescence are 
decoy receptor 2 (DCR2), differentiated embryo chondrocyte expressed gene 1 (DEC1) and 
senescence-associated heterochromatin foci (SAHF) (Xu et al., 2012). 
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1.5.3   Cellular Senescence-signalling pathways 
Cyclin-Dependent Kinases (CDKs) regulate multiple proteins involved in cell cycle 
progression (Suryadinata et al., 2010). Senescent cells undergo cell-cycle arrest through CDK 
inhibitors which is encoded in the CDKN2A (p16INK4a/p16 and p14ARF/p14), CDKN2B (p15) 
and CDKN1A (p21) loci.  
Senescence-inducing signals, such as telomere attrition, DNA damage, oxidative stress, 
oncogenes, excessive mitogenic signalling and many others, may trigger DNA-damage 
response (DDR) as well as many other stresses that further engage either in p53 dependent 
(p53-p21) or p53 independent (p16-RB) pathway inducing cellular senescence (Campisi & 
d'Adda di Fagagna, 2007; Gorgoulis & Halazonetis, 2010; Lämmermann et al., 2018).  
Figure 6 illustrates the two major pathways through which senescence happens.  
p16 is an inhibitor of Cyclin dependent kinase 4 and 6 (CDK4/6), that prevents 
phosphorylation of retinoblastoma protein. Hypophosphorylated RB halts cell proliferation 
by suppressing the E2F activity, a transcription factor that induces the expression of genes 
necessary for cell-cycle progression (Narita et al., 2003). Studies have correlated the levels of 
p16 with the chronological aging of tissues that are analyzed in both mice and humans which 
highlights the importance of p16 as a biomarker to detect senescent cells (Krishnamurthy et 
al., 2004; Ressler et al., 2006; Baker et al., 2011; Burd et al., 2013). Alternate reading frame 
(ARF) protein has been shown to inactivate p53 degrading E3 ubiquitin-protein ligase HDM2 
(MDM2 in mice) in such a way that it maintains p53 stability (Kim & Sharpless, 2006; Gil & 
Peters, 2006). p53 transactivates p21 (cyclin-dependent kinase (CDK) inhibitor) expression 
(Hernandez-Segura et al., 2018), which suppresses the phosphorylation of RB leading to cell 
cycle arrest resulting in senescence.  
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Figure 6: Illustration of senescence pathways. Various senescence-inducing signals trigger 
cells to undergo senescence through either p53-p21 axis and/or p16-Rb axis, which are two 
major pathways for senescence.  
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p15 (CDKN2B) has similar structure, function and biochemical properties like p16; however 
not much attention has been given to p15 in the context of senescence mechanism (Li et al., 
2011) as p16 is recognized widely as an important marker for senescence.  
1.5.4   Senescence-Associated Secretory Phenotype (SASP) 
In a landmark study by Coppé et al. (2008), the authors demonstrated that senescent cells 
when induced by genotoxic stress secrets a complex number of factors that are associated 
with inflammation. This was termed as Senescence-Associated Secretory Phenotype (SASP). 
Though senescent cells stop dividing, they still remain metabolically active and implement a 
complex pro-inflammatory response secreting cytokines, chemokines, interleukins and 
proteinases that are collectively known as SASP (Kuilman & Peeper, 2009; Evan & d'Adda 
di Fagagna, 2009; Coppé et al., 2010; Campisi, 2013). The SASP is mediated by the 
transcription factors such as nuclear factor-κB (NF-κB), GAT4A 
and CCAAT/enhancerbinding protein-β (C/EBPβ) (Acosta et al., 2008; Rovillain et al., 2011; 
Kang et al., 2015). NFkB mainly induces the expression of inflammatory cytokines such as 
IL-1β, IL-6 and TNF-α. Apart from this, Jak2/ Stat3 pathway is another pathway that 
upregulates immunosuppressive cytokines such as, IL-10, IL-13, M-CSF, GM-CSF, 
CXCL1/CXCL2 (Hayakawa et al., 2015). SASP components such as TGFβ can induce 
senescence on its own in neighbouring cells in a paracrine manner (Hubackova et al., 2012; 
Nelson et al., 2012; Ritschka et al., 2017).  
1.5.5   Cellular Senescence and Diabetes 
Senescence is considered to play a prominent role in the pathogenesis of age-associated 
diseases like diabetes (Palmer et al., 2015). The association between type 2 diabetes and 
senescence is complex. Whether senescence is the cause for disease or the senescence is a 
consequence of pathology of the disease is still under debate (Childs et al., 2015). 
Several in vitro studies have shown that high glucose exposure which mimics 
hyperglycaemic condition, is capable of inducing cellular senescence in various tissue models 
such as fibroblasts, endothelial cells, mesenchymal cells, and adipose-derived stem cells 
(Blazer et al., 2002; Yokoi et al., 2006; Cramer et al., 2010; Legzdina et al., 2016; Zhang et 
al., 2017). Ksiazek et al. (2008) predicted mitochondrial dysfunction, over production of 
reactive oxygen species, or DNA damage as mechanism through which high glucose induces 
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accelerated senescence. Cellular senescence may accompany mitochondrial dysfunction that 
causes oxidative stress related to the development of insulin resistance in ageing muscle 
tissues (Petersen et al., 2003; Passos et al., 2010). Studies have reported age-associated 
reduction in the proliferative potential, through senescence in pancreatic β-cells, as the cause 
for the pathogenesis and increased prevalence of T2DM among elderly population (Sone & 
Kagawa, 2005; Helman et al., 2016).   
Starting from the study by Adaikalakoteswari et al. (2005) which demonstrated an association 
of increased telomere shortening in patients with T2DM, several studies attested that there 
exists a link between accelerated senescence (ageing) and T2DM (Adaikalakoteswari et al., 
2007; Balasubramanyam et al., 2007; Monickaraj et al., 2012; Monickaraj et al., 2013). 
Several GWAS studies have revealed that polymorphisms in close proximity to CDKN2A 
(p16INK4a/p14ARF) and CDKN2B (p15) locus, which are a major locus for senescence 
associated genes, are genetically linked to several age-associated pathologies that includes 
type 2 diabetes cardiovascular complications, glaucoma and Alzheimer’s (Doria et al., 2008; 
Jeck et al., 2012). Baker et al. (2011) demonstrated in a mouse model that by eliminating 
p16-positive senescent cells, age-related pathologies can be delayed.  
Senescence-associated secretory phenotypes, such as MCP-1, IL-6 and IL-8, are notably 
increased in obese individuals and contribute to the pro-inflammatory state (Kim et al., 2006; 
Freund et al., 2010). This inflammation is reported to be a major contributing factor in the 
development of insulin resistance (Xu et al., 2003; Esser et al., 2014). These results attest that 
there is a strong interlink between diabetes and cellular senescence.  
The detailed literature on the possible role of BPA in the pathogenesis of diabetes warrant 
more clinically relevant studies backed up by studies in animal model and metabolic tissues 
and this thesis has been holistically focused on this directionality.   
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1.6   Research Gaps 
 Despite the worldwide concern on the BPA and environmental health, there is a lack 
of data on the circulatory levels of BPA in relation to type 2 diabetes and obesity in 
the clinical context in India. 
 Several studies that involved in vivo models, were only focused on consequence of 
BPA exposure on metabolic disorders rather than focusing on the context of 
pathophysiology of the disease. 
 While the review of literature accounts for the varied tissue-specific effects of BPA 
on metabolism, there is lack of research that systematically studies the effects of BPA 
on pathway-specific molecular alterations with a disease-biology focus and using the 
state-of-the-art molecular tools. 
 
Our study tried to address these research gaps and create a knowledge pool for 
future studies of translational research.  
 
1.7   Rationale behind this study 
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1.8   Study Objectives 
 To investigate the circulating levels of BPA in subjects with type 2 diabetes compared 
to control subjects (normal glucose tolerant individuals) and to derive an association 
with glycemic control, insulin resistance, and senescence.  
 To investigate the causative mechanism of BPA in the pathogenesis of metabolic 
disease like hyperglycemia using zebrafish as an in vivo animal model.  
 To study the tissue-specific (skeletal muscle) effects of BPA on senescence 
mechanisms and glucose metabolism.    
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Chapter 2 
Elevated systemic levels of bisphenol-A (BPA) are linked 
to poor glycemic control, cellular senescence and insulin 
resistance in   patients with Type 2 Diabetes 
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2.1   Abstract  
Evidences are accumulating to point out an interaction of genes and environment in the 
etiology of type 2 diabetes (T2DM). Recently, endocrine disrupting chemicals (EDCs) like 
bisphenol-A (BPA) have received special attention for their mechanistic role in metabolic 
disruption. Despite the increasing awareness on the role of BPA in the development of insulin 
resistance and T2DM, there is a lack of clinically relevant data regarding Asian Indians, a 
population which is more susceptible to T2DM and other metabolic disorders. Therefore, the 
objective of this study is to measure systemic levels of BPA in patients with T2DM (n=30) 
compared to control individuals with normal glucose tolerance (n=30) and to assess its status 
for correlation with other risk variables. Serum BPA levels were estimated using ELISA kit 
and biochemical determinations were done by standard protocols. In addition, we have also 
utilized peripheral blood mononuclear cells (PBMCs) to profile the gene expression 
alterations with special reference to inflammation, estrogen receptors and cellular senescence 
in these subjects. Serum levels of BPA was significantly higher in patients with T2DM 
compared to control individuals. BPA levels in T2DM subjects were also positively 
correlated to poor glycemic control and insulin resistance. Gene expression analysis in 
PBMCs revealed that patients with T2DM exhibited significantly elevated mRNA levels of 
senescence (GLB1, p16, p21 and p53) and inflammatory (IL6 and TNF-α) markers. The 
chronic burden of senescence and inflammation was also reflected by significantly reduced 
and shortened telomeres in patients with T2DM compared to control subjects. Interestingly, 
PBMCs from patients with T2DM also exhibited significantly elevated mRNA expression of 
ERRγ, a recently identified receptor for BPA. This study is the first to demonstrate an 
association of increased BPA levels with cellular senescence, pro-inflammation, poor 
glycemic control, insulin resistance and shortened telomeres in patients with T2DM. 
Studying the biological consequences of cellular alterations of BPA is expected to unravel 
novel drug targets and development of newer therapeutic measures. 
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2.2   Introduction: 
The emergence of type 2 diabetes mellitus (T2DM) as a global epidemic as well as pandemic 
is one of the major challenges to human health in the 21st century (Jaacks et al., 2016). 
According to the latest International Diabetes Federation (IDF) Atlas, around 425 million 
people worldwide are diagnosed with diabetes and India alone harbours more than 73 million 
of individuals with diabetes (IDF, 2017). T2DM is conceived as a metabolic (Marin et al., 
2018) and vascular disease (Hayward et al., 2015), who’s pathogenesis originates from 
multiple cellular alterations (Geraldes & King, 2010) and gene-environment interactions 
(Kaul & Ali, 2016). Peripheral insulin resistance in combination with impaired pancreatic β-
cell function leads to the clinical manifestation of T2DM (Defronzo, 2009). Recent genome 
wide association studies (GWAS) have identified ~120 genetic variants linked to diabetes; 
however, these genetic variants could explain only 10-15% of disease risk, while the 
remaining >80% of risk is not yet clearly understood and often suggested to be product of 
gene-environment interactions (Imamura et al., 2016). In this context, environmental 
contaminants such as endocrine disrupting chemicals (EDCs) received special attention in 
causing the metabolic disruption in relation to obesity, insulin resistance, T2DM and other 
metabolic diseases (Chevalier & Fenichel, 2016; Mimoto et al., 2017; Heindel et al., 2017). 
Among EDCs, bisphenol A (BPA), which mimics natural endogenous estrogen, has been 
reported to be involved in the pathogenesis of several diseases and, over the last decade, it 
has been claimed to have potential diabetogenic and obesogenic actions (Fenichel et al., 
2013; Provvisiero et al., 2016). While several epidemiological studies have suggested that 
BPA exposure is positively associated with an increased risk of T2DM (Sowlat et al., 2016; 
Provvisiero et al., 2016; Chailurkit et al., 2017), there is lack of data on this in Asian Indians, 
a population highly prone to the epidemic of diabetes and its vascular complications (Gujral 
et al., 2015). 
T2DM among Asian Indians is characterized by the onset at a younger age, greater 
abdominal obesity despite of having relatively lower BMI, greater insulin resistance, and 
early decline in beta cell function (Shah & Mohan, 2015). Tissue dysfunction occurs with 
aging (McHugh & Gil, 2018) and has systemic effects, including peripheral insulin 
resistance, inflammation, ectopic lipid accumulation and accelerated senescence, may have a 
causal role in the pathogenesis of T2DM (Le Lay & Dugail, 2009; Palmer et al., 2015).  
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Senescent cells may play a role in the pathogenesis of T2DM by impacting pancreatic β-cell 
function, senescence-associated secretory phenotype (SASP) mediated tissue damage, and 
involvement in multiple tissue defects (Regulski, 2018). One of the well-established features 
of senescence is the up regulation of p16-RB and/or p53-p21 proteins which typically 
involves in the inhibition of cyclin dependent kinase activity resulting in cell cycle arrest 
(López-Otín et al., 2013; Althubiti et al., 2014; Caliò et al., 2015). Hence, it becomes 
important for our study to analyze the expression levels of these genes as an indicator of 
senescence.  Increased levels of lysosomal enzyme and its activity is a hallmark of 
senescence (Wagner et al., 2015). Thus, increased GLB1 gene (β-gal) expression which 
encodes lysosomal enzyme was used as one of the markers of senescence in this study.  
SASP, which is produced in senescent cell comprises of pro-inflammatory cytokines, growth 
factors that alters tissue microenvironments and induce malignant phenotypes in nearby cells 
(Watanabe et al., 2017). TNF- α and IL-6 are among the major secreted pro-inflammatory 
cytokines during senescence (Tchkonia et al., 2013; Prattichizzo et al., 2016; Meyer et al., 
2017) that are also shown to be elevated during the pathogenesis of T2DM (Mirza et al., 
2012). Our study analysed the expression patterns of these inflammatory and associated 
markers like suppressor of cytokine signalling 3 (SOCS3), which is a major regulator of 
inflammatory cytokines among SOCS family of proteins (Carow & Rottenberg, 2014; Liu et 
al., 2015).   
In one of our pioneering works (Adaikalakoteswari et al., 2005), we have reported increased 
shortening of telomeres in patients with T2DM. Telomere shortening is also a validated 
biomarker for cellular senescence (Bernadotte et al., 2016). In addition to the comparison of 
telomere length between diabetic subjects and normal subjects, our study also examined the 
correlation between BPA levels found in the study participants with the telomere length, 
which we believe will show the impact of BPA exposure on telomere length.   
Our study also focused on analysing the expression levels of several other important genes 
such as estrogen receptors, estrogen related receptors, AR, AHR, NOD-1, NOD-2 and 
metabolic receptors that are involved in the BPA mechanism of action in the pathogenesis of 
metabolic diseases.  
While BPA exposure has been linked to DNA damage and senescence (Qin et al., 2012; Herz 
et al., 2017), there is lack of data on the cellular and molecular alterations in the clinical 
setting. With this background, the present study has determined the systemic levels of BPA in 
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patients with T2DM compared to healthy individuals and have assessed the biochemical and 
molecular correlations with special reference to senescence and inflammatory markers. 
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2.3   Methodology 
Most of the methods followed in this chapter was adopted from Sathish et al. (2016) and 
other collegues from Madras Diabetes Research Foundation.  
2.3.1   Ethical Statement 
Human research ethics approval was obtained from the Institutional Ethics Committe (IEC) 
of Deakin University as well as Madras Diabetes Research Foundation according to national 
guidelines: DU-HREC:2015-169. The study was conducted adhering to the principles of 
Declaration of Helsinki.  
2.3.2   Recruitment of study participants 
The study participants were recruited from the on-going epidemiology studies at the Madras 
Diabetes Research Foundation and from Dr. Mohan’s Diabetes Specialities Centre, a tertiary 
diabetes centre at Chennai, South India. The study groups comprised of participants (age 
between 35 and 55 years) with normal glucose tolerance subjects (NGT, n=30) and patients 
with Type 2 Diabetes mellitus (T2DM, n=30) clinically well-characterized based on World 
Health Organization (WHO) criteria for the diagnosis of diabetes. According to WHO, 
subjects with fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L) and/or 2 hours plasma 
glucose concentration ≥ 200 mg/dL (11.1 mmol/L) after orally consuming 75 grams of 
anhydrous glucose in an oral glucose tolerance test (OGTT) are classified as diabetes. 
Subjects with fasting plasma glucose <100 mg/dL and a 2-hour post load plasma glucose of 
<140 mg/dL are classified as normal glucose tolerant subjects.  
Fasting blood samples were collected in the presence and absence of anticoagulant tubes and 
samples were centrifuged at 4,000 rpm (rotations per minute) for 10 minutes, followed by 
12,000 rpm for 15 minutes to completely remove cell debris and serum was stored at -80°C in 
BPA-free polypropylene cryo-tubes (Catalog#FC430488, Corning) and was handled 
separately for BPA estimation. 
2.3.3   Anthropometric measurements 
Anthropometric measurements that includes height, weight and waist circumference were 
measured using standardized techniques. Height was noted down using a tape measured to 
the nearest centimeter. Weight was measured in kilograms using electronic weighing machine 
that was kept on a firm horizontal surface. Waist circumference was measured by a non-
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stretchable fiber measuring tape. Body Mass Index (BMI) which is a simple index commonly 
used for determining underweight, overweight and obesity in adults (WHO) was calculated as 
the weight in kilograms divided by height in metre square (kg/m2). Blood pressure was 
recorded from the right arm in a sitting position to the nearest 2 mmHg using mercury 
sphygmomanometer (Diamond Deluxe BP apparatus, Pune, India). Readings were recorded 
twice in the interval of 5 minutes and the mean of those was taken as blood pressure. 
2.3.4   Biochemical estimation 
Biochemical estimation of fasting plasma glucose (glucose oxidase-peroxidase method), 
serum triglycerides (glycerol phosphate oxidase-peroxidase-amidopyrine method), serum 
cholesterol (cholesterol oxidase-peroxidase-amidopyrine method), and HDL cholesterol (by 
direct method-polyethylene glycol-pre-treated enzymes) were measured using Hitachi-912 
Autoanalyser (Hitachi, Mannheim, Germany). The inter assay and intra assay coefficient of 
variation for these biochemical assays were lesser than 5%. Low-density lipoprotein (LDL) 
cholesterol was estimated using the Friedewald formula (Friedewald et al., 1972). Glycated 
haemoglobin (HbA1c) was measured using high-pressure liquid chromatography (HPLC) 
with the variant machine (Bio-Rad, Hercules, Calif., USA). Serum Insulin level was 
estimated by enzyme-linked immunosorbent assay (Catalog#IS130D, Calbiotech, CA). The 
inter-assay and intra-assay coefficients of variation for the insulin assay were lesser than 9%. 
Insulin resistance was calculated using the homeostasis assessment model (HOMA-IR) 
formula: (Fasting insulin (µIU/mL) x Fasting glucose (mmol/L)) / 22.5.  
2.3.5   Quantification of serum Bisphenol-A 
To estimate total BPA, serum samples (100 µL) was hydrolyzed by adding 215 µL of serum 
β-glucuronidase enzyme (Catalog#G0751-100 KU, Sigma-Aldrich) to serum samples and 
this mixture was incubated at 37°C for 16 hours. After incubation, samples clean-up was 
performed using StrataTM X 33 µm Polymeric Reversed Phase 60 mg/3 mL, tubes 
(Catalog#8B-S100-UBJ, Phenomenex, India). Strata X column was pre-conditioned with 
absolute methanol and distilled water, followed by addition of hydrolyzed serum sample 
mixtures into the column. Final elute was collected in glass tube and samples were air dried 
using nitrogen gas and the dried product was reconstituted in 10% methanol and it was used 
for investigation. Total BPA (Free and conjugated) from serum was measured in the 100 µL 
of serum sample using Super sensitive ELISA kit (Catalog#92893, Ecologiena, 
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EnviroChemical, Ltd.) as per manufacturer instruction. The intra-assay and the inter-assay 
coefficient of variation for the assay were <12% and <8% respectively.  
2.3.6   Preparation of peripheral blood monolayer cells and RNA isolation 
Whole blood (10 ml) was collected in EDTA tube from all the study subjects. Peripheral 
blood monolayer cells (PBMC) were isolated using Histopaque (Catalog#1077, Sigma-
Aldrich) following the standard protocol. Blood was overlaid on the density gradient solution 
and centrifuged at 1500-1800 rpm for 30 minutes. The buffy coat layer that contained 
PBMCs were collected and washed with phosphate buffered saline (PBS, pH 7.2-7.4). 
Isolated PBMCs were used immediately for total RNA extraction.  
2.3.7   Total RNA extraction and first strand cDNA synthesis 
Total RNA was extracted from PBMCs using Trizol reagent (Catalog#9109, RNAiso Plus, 
Takara) as per manufacturer’s instruction and RNA was eluted using 100 µl of nuclease free 
water. The total RNA quality and the quantity were measured using NanoDrop 2000 (Thermo 
Scientific) and RNA samples were stored at -80°C. First strand cDNA was synthesized using 
1 µg of total RNA, 40 µM Oligo-dT18 primer (New England Biolabs), 10x RT buffer and 2.5 
mM each of dNTPS and 100 units reverse transcriptase enzyme. The reaction condition 
includes 42°C for 1 hour which is followed by 95°C for 5 minutes to heat inactivate the 
enzyme. 
2.3.8   Gene expression by Real-time PCR 
Quantitative real-time PCR was performed for specific genes by preparing reaction mixture 
with SYBR green master mix (Catalog#F416S Dynamo Color flash Sybr Green QPCR Kit). 
PCR amplification was carried out using LC -96 (Light cycler 96, Roche cycle) with the 
following cycle conditions: Initial cycle at 50°C for 2 minutes, Initial denaturation at 95°C 
for 15 minutes, 45 cycles of denaturation at 95°C for 15 seconds and Annealing/Extension at 
60°C for 1 minute). The relative quantification was calculated using 2–ddct method and 
normalized by β-actin. List of genes analyzed in this study are as follows: β-actin, GLB1 (β-
Gal), p16, p21, p53, ER-α, ER-β, ERR-α, ERR-β, ERR-γ, Socs-3, IL-6, TNF-α, CYP2C9, 
CYP2C18, AHR, AR, NOD-1, NOD-2, GPER-1 and PPAR-γ. List of primers used were 
given in Table 1. 
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2.3.9   Telomere length measurement by Real-time PCR 
For the measurement of telomere length, DNA was isolated using back extraction method 
(Triant & Whitehead, 2009). Real-time PCR was used to determine the length of telomere as 
previously described (Monickaraj et al., 2012). 30 ng of DNA was used for the experiment. 
Amplification was carried out using LC-96 (Light cycler 96, Roche cycle) with cycle 
conditions (45 cycles of 95°C for 15 seconds, 60°C for 1 minute). Telomere length (TL) was 
expressed as a ratio of number of repeated copies of the telomere (T) over single gene copy 
number (T/S). The beta-hemoglobin gene (36B4) was used as a reference single-copy gene. 
Primers used were given in Table 1. 
Gene Forward Primer (5’ - 3’) Reverse primer (5’ - 3’) 
β-ACTIN ACCTTCTACAATGAGCTGCG CTGGATGGCTACGTACATGG 
GLB1 ACGGTGGACTTTGGAACAG TGATTGTGGAGTGAGGTTGG 
p16 GATGTCGCACGGTACCTG TCTCTGGTTCTTTCAATCGGG 
p21 TGTCACTGTCTTGTACCCTTG GGCGTTTGGAGTGGTAGAA 
p53 GCCATCTACAAGCAGTCACAG TCATCCAAATACTCCACACGC 
IL-6 TGGATTCAATGAGGAGACTTG TGTTCTGGAGGTACTCTAGG 
TNF-α GGACGAACATCCAACCTTCCC GTGGTCTTGTTGCTTAAAGTTCTAAG 
SOCS-3 TCGATTCGGGACCAGC GCGGGAAACTTGCTGT 
ER-α CGACTATATGTGTCCAGCCAC CCTCTTCGGTCTTTTCGTATCC 
ER-β GGTCGTGTGAAGGATGTAAGG TTCCCACTTCGTAACACTTCC 
ERR-α TGCCAATTCAGACTCTGTGC CCAGCTTCACCCCATAGAAA 
ERR-β GCAAAGTGCCCATGCACAAA TGATCCCTGCTTGTGAAGGC 
ERR-γ GAAATCACAAAGCGCAGACG CTGTTCTCCGCATCTATCCTG 
NOD-1 ACAATCTCAACGACTACGGC CTTAGCACCTTTACCCCACC 
NOD-2 AACTCTGTGGGTGACATTGG GATGCCTCGGTCTGAGATATTG 
GPER-1 CATTCCAGACAGCACCGAG AGTTTAGAGACATGACGTGGC 
PPAR-γ TCTCTCCGTAATGGAAGACC GCATTATGAGACATCCCCAC 
AHR CCAACATCACCTACGCCAG CCAAACGGTCCAACTCTGTAT 
AR AATCCCACATCCTGCTCAAG AAGTCCACGCTCACCATG 
CYP2C9 CACGAGGTCCAGAGATACATTG CATGTAGCACAGAAGTCAGGG 
CYP2C18 AACATCCCTGACTTCTGTGC TCTCCCATACACATCCGTTTTC 
36B4 CAGCAAGTGGGAAGGTGTAATCC CCCATTCTATCATCAACGGGTACAA 
TELOMERE CGGTTTGTTTGGGTTTGGGTTTGGGT GGCTTGCCTTACCCTTACCCTTACCC 
  TTGGGTTTGGGTT  TTACCCTTACCCT 
 
Table 1:  Shows the list of primers used in this study for real time PCR. 
 
 46 
 
2.3.10   Statistical analysis 
All the data were expressed as Mean ± SEM or Mean ± SD. Comparisons between groups 
were performed using unpaired student’s t-test. Pearson correlation analysis was performed to 
determine the relation between BPA levels with other variables such as metabolic risk 
variables and gene expression. The correlation is done between BPA levels and other 
variables irrespective of the disease status of an individual. Binary logistic regression analysis 
was used to determine the association of independent molecular signatures with BPA. p-value 
<0.05 was considered statistically significant. All the statistical analyses were carried out 
using Windows based Statistical Package for Social Science (SPSS Version 20, Chicago, IL). 
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2.4   RESULTS 
2.4.1   Clinical & Biochemical characteristics of the study groups 
Clinical and biochemical characteristics of the study subjects were given in Table 2. BMI 
was significantly higher in T2DM patients compared to control participants. Patients with 
T2DM exhibited significant increase (p<0.05) in fasting plasma glucose levels, 2 hours post 
glucose levels and HbA1c compared to the control subjects. Patients with T2DM were also 
insulin-resistant as characterized by the significant elevation in HOMA-IR values. Compared 
to control subjects, there were also significant higher levels of lipids (total cholesterol, 
triglyceride and VLDL cholesterol) in patients with T2DM. 
 
  Normal Glucose Tolerance Type 2 Diabetes Mellitus  
   (NGT) (T2DM) 
Male/Female (15/15) (16/14) 
Age (years) 43.5 ± 6.1 48.5  ± 6.7* 
Body Mass Index (kg/m2) 25.5  ± 3.9 27.7  ± 3.7* 
Waist/Hip 0.92  ± 0.1 0.95  ± 0.1 
Fasting plasma glucose (mg/dL) 91.2  ± 8.3 132.3  ± 35.1* 
2 hours plasma glucose (mg/dL) 103.8  ± 16.9 271.7  ± 62.9* 
Fasting Insulin (uIU/mL) 9.43 ± 5.6 10.9 ± 6.1 
HOMA IR 2.1 ± 1.4 3.5 ± 1.9* 
HbA1c (%) 5.5  ± 0.4 7.2  ± 1.2* 
Total Cholesterol (mg/dL) 175.1  ± 33.2 193.7  ± 30.4* 
Serum Triglyceride (mg/dL) 116.3  ± 58.7 168.4  ± 78.2* 
LDL  Cholesterol  (mg/dL) 108.4 ± 29.1 117.6  ± 26.4 
HDL  Cholesterol  (mg/dL) 43.33  ± 11.1 41.3  ± 8.5 
VLDL  Cholesterol (mg/dL) 23.4  ± 11.7 32.4  ± 13.0* 
Systolic Blood Pressure (mm/Hg) 122.4 ± 18.6 127.5 ± 9.7 
Diastolic Blood Pressure (mm/Hg) 79.1 ± 11 81.6 ± 7.1 
 
Table 2 shows the clinical characterization of the study subjects. Comparison is between 
type 2 diabetes subjects (n=30) with normal glucose tolerant subjects (n=30). Data 
represented as mean ± SD. *p<0.01 compared to NGT subjects. 
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2.4.2   Systemic BPA levels in the study participants 
Serum BPA levels (Mean ± SEM) in patients with T2DM (52.4±3.8 µg/L) were found to be 
significantly higher (p<0.05) compared to NGT individuals (41.7±3.0 µg/L) (Fig 1). T2DM 
subjects showed approximately, a 0.3 fold increase in BPA levels over NGT subjects, which 
was visible between the groups.  
 
                       
 
Figure 1: Elevated BPA levels in the patients with type 2 diabetes: Serum BPA 
concentration quantified from patients with type 2 diabetes (n=30) and normal glucose 
tolerance (n=30). Bars represent the mean ± standard mean error. *p<0.01 compared to 
control subjects. 
 
 
 
2.4.3 Transcriptional levels of senescence, inflammatory, estrogen and metabolic 
receptor markers: 
Gene expression amplified by Real-time PCR and sequences of the primers used for their 
amplification are depicted in Table 2. Figure 2 shows PBMCs gene expression levels of 
senescence markers (GLB1, p16, p21 and p53) in T2DM patients compared to NGT 
individuals. All the senescence markers were found significantly elevated in PBMCs from 
patients with T2DM compared to NGT. GLB1 expression showed an increase in expression 
levels in T2DM by ~0.4 fold of the control and p16 expression levels showed an increase in 
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T2DM by ~0.8 fold of the control. Whereas, gene expression levels of p21 and p53 in T2DM 
subjects showed significant increase by ~0.6 fold of the NGT. The process of senescence is 
not limited to cell cycle arrest. Senescent cells are metabolically active and acquire the state 
of Senescence Associated Secretary Phenotype (SASP) (Wiley & Campisi, 2016). Therefore, 
we analyzed the gene expression state of pro-inflammatory signatures in these cells. As 
shown in Figure 3, transcriptional levels of inflammation and associated markers (IL-6, 
TNF-α and SOCS-3) were found significantly elevated in patients with T2DM compared to 
control subjects. IL-6 and TNF-α showed significant increase in T2DM by ~0.6 and ~0.7 fold 
of the NGT respectively, while SOCS-3 had ~1.1 fold significant increase in T2DM over 
NGT. This is indicative of presence of increased SASP in T2DM subjects which is a 
component of senescence process. 
 
Figure 2 (A-D): Gene expression analysis of senescence markers: Real-time quantitative 
RT-PCR analysis of mRNA expression levels of Senescence markers- (A) GLB1 (β-GAL), 
(B) p16, (C) p21, (D) p53. All the senescence markers are seen significantly elevated in 
T2DM subjects (n=30) compared to NGT subjects (n=30). Bars represent the mean ± 
standard mean error. *p<0.05 vs NGT.  
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Figure 3 (A-C): Gene expression analysis of Inflammatory markers: Real-time 
quantitative RT-PCR analysis of mRNA expression levels of inflammatory markers-          
(A) IL-6, (B) TNF-α, (C) Socs-3. All the three inflammatory markers are seen significantly 
elevated in T2DM subjects (n=30) compared to NGT subjects (n=30). Bars represent the 
mean ± standard mean error. *p<0.05 vs NGT.  
 
 
 
Among the profiled gene expression levels of various estrogen receptors (ER-α, ER-β) and 
estrogen related receptors (ERR-α, ERR-β, ERRγ), expression levels of ERRγ were found 
significantly elevated in T2DM patients which is ~0.6 fold of the NGT (Figure 4). Among 
the other transcriptional signatures tested, gene expression levels of PPARγ and NOD-2 
showed ~1.5 fold and ~0.4 fold respectively, significant increase in patients with T2DM over 
NGT (Figure 5), whereas receptors like Aryl Hydrogen receptor (AHR), Androgen receptor 
(AR), GPER-1 and NOD-1 did not show differential expression with statistical significance. 
Interestingly, BPA metabolism related enzyme like CYP2C9 showed an increase in 
expression levels in T2DM by ~1.2 fold of the NGT (Figure 5).  
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Figure 4 (A-E): Gene expression analysis of estrogen and estrogen related receptors: 
Real-time quantitative RT-PCR analysis of mRNA expression levels of estrogen receptors- 
(A) ER-α and (B) ER-β; and estrogen related receptors- (C) ERR-α, (D) ERR-β, (E) ERR-γ. 
No significant difference is seen in any of the receptor mRNA levels apart from ERRγ, which 
was found to be significantly increased in T2DM subjects (n=30) compared to NGT subjects 
(n=30). Bars represent the mean ± standard mean error. *p<0.05 vs NGT.  
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Figure 5 (A-H): Gene expression analysis of metabolic receptors: Real-time quantitative 
RT-PCR analysis of mRNA expression levels of (A) NOD-1, (B) NOD-2, (C) AR, (D) AHR, 
(E) GPER-1, (F) PPARγ, (G) CYP2C9, (H) CYP2C18. No significant difference was seen in 
any mRNA levels of NOD-1, AR, AHR, GPER-1 and CYP2C18. Significant increase in 
mRNA expression of NOD-2, PPARγ and CYP2C9 are seen in T2DM subjects (n=30) 
compared to NGT subjects (n=30). Bars represent the mean ± standard mean error. *p<0.05 
vs NGT.  
 
 
 
 
 
 
 
 53 
 
2.4.4   Shortened telomeres in patients with T2DM  
Consistent with the accelerated senescent markers at the transcriptional level, patients with 
T2DM exhibited significantly shorter telomeres compared to NGT subjects (Figure 6). Mean 
± SD of telomere length (T/R ratio) of T2DM and NGT subjects were (1.42 ± 0.04) and (1.44 
± 0.04) respectively.  
 
 
                    
Figure 6: Telomere length as measured by Real-time PCR. Telomere length in T2DM 
subjects (n=30) were significantly lesser when compared to NGT subjects (n=30). Bar 
diagram represent T/S ratio in the patient with T2DM and NGT with ± SD. *p<0.05 vs. 
NGT.   
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2.4.5   Correlation between BPA levels and Biochemical parameters/Molecular 
signatures 
Biochemical parameters like plasma glucose (Correlation coefficient (r) =0.400, p=0.002), 
HbA1c (r=0.395, p=0.002), triglyceride (r=0.417, p=0.001), and VLDL (r=0.381, p=0.003) 
were significantly and positively correlated with BPA levels while there was a negative 
correlation between HDL and BPA levels (r=-0.352, p=0.006). Insulin resistance HOMA-IR 
showed positive correlation with BPA levels (r=0.356, p=0.006). Senescence indicators: 
GLB1 (r=0.414, p=0.001), p16 (r=0.353, p=0.006), p21 (r=0.375, p=0.003), p53 (r=0.279, 
p=0.032), inflammatory markers: TNF-α (r=0.309, p=0.017) and IL-6 (r=0.294, p=0.024) and 
receptors like ERRγ (r=0.284, p=0.029), GPER-1 (r=0.256, p=0.05) and AHR (r=0.304, 
p=0.019) were significantly and positively correlated with BPA levels. Telomere length 
showed negative correlation with BPA levels (r=-0.256, p=0.049) (Table 3).  This indicates 
that as the level of BPA increases the telomere length reduces. This is the first study to report 
a negative correlation between BPA levels and telomere length in a clinical setup.   
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Clinical parameter and mRNA 
levels BPA levels 
 r-value p-value 
Fasting plasma glucose (mg/dL) 0.400* 0.002 
2 hours plasma glucose (mg/dL) 0.395* 0.002 
HOMA-IR 0.356* 0.006 
HbA1c (%) 0.338* 0.009 
Body Mass Index (BMI) (kg/m2) -0.103 0.438 
Weight/Hip Ratio 0.226 0.086 
Total Cholesterol (mg/dL) 0.092 0.488 
Triglyceride (mg/dL) 0.417* 0.001 
HDL Cholesterol (mg/dL) -0.352* 0.006 
LDL Cholesterol (mg/dL) -0.034 0.798 
VLDL  Cholesterol (mg/dL) 0.381* 0.003 
Systolic Blood Pressure (mm/Hg) 0.013 0.925 
Diastolic Blood Pressure (mm/Hg) 0.187 0.155 
GLB1 0.414* 0.001 
p16 0.353* 0.006 
p21 0.375* 0.003 
p53 0.279* 0.032 
SOCS-3 0.166 0.208 
IL-6 0.294* 0.024 
TNF-α 0.309* 0.017 
ER-α 0.140 0.29 
ER- β 0.148 0.264 
ERR-α 0.095 0.473 
ERR- β -0.011 0.936 
ERRγ 0.284* 0.029 
GPER-1 0.256* 0.05 
AHR 0.304* 0.019 
AR -0.063 0.633 
PPAR γ 0.112 0.397 
NOD-1 0.074 0.575 
NOD-2 0.176 0.183 
CYP2C9 0.134 0.311 
CYP2C18 -0.159 0.228 
Telomere Length -0.258* 0.049 
 
Table 3: Pearson correlation analysis of serum BPA levels with biochemical parameters 
and gene expression in the study subjects. Adjusted for age. *p<0.005 indicates significance.   
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2.4.6   Association analysis 
Binary logistic regression analysis was performed to identify the association between BPA 
and diabetes. Unadjusted BPA showed significant association with diabetes (β-value 1.032, 
CI- 1.002-1.063, p<0.05). When adjusted for confounding factors like age, gender and BMI, 
BPA was still significant (β-value 1.052, CI- 1.011-1.096, p<0.05). Whereas, when adjusted 
with HOMA-IR, senescence markers (GLB1, p16, p21, p53), and inflammatory markers 
(Socs-3, IL-6 and TNF-alpha), ERRγ, and telomere length, it lost its significance indicating 
that BPA was associated with above markers (Table 4).  
 
Parameters β-value 
  
p-value 95% C.I. for EXP(B) 
  
Dependent Variable: T2DM       
BPA unadjusted 1.032 1.002-1.063 0.036 
BPA adjusted For:       
Age, Gender, BMI 1.052 1.011-1.096 0.014 
Age, Gender, BMI, HOMA IR 1.033 0.990-1.078 0.134 
Senescence Markers (GLB1, p16, p21, 
p53) 1.017 0.984-1.052 0.311 
Inflammatory Markers (SOCS-3, IL-6, 
TNF-α ) 1.016 0.979-1.054 0.411 
ERRγ 1.024 0.993-1.056 0.126 
Telomere Length 1.027 0.996-1.059 0.091 
 
Table 4: Binary logistic regression analysis of serum BPA levels with biochemical 
parameters and gene expression in the study subjects. *p<0.005 indicates significance. 
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2.5   Discussion 
Increasing exposure to EDCs is suspected as a contributive factor to T2DM along with 
known causes such as reduced insulin sensitivity, obesity and defective β-cell mass and 
function (Ashley-Martin et al., 2014; Garcia-Arevalo et al., 2015). Several epidemiological 
studies found higher BPA and chlorinated BPA levels to be associated with T2DM (Shankar 
& Teppala, 2011; Sun et al., 2014; Aekplakorn et al., 2015; Andra et al., 2015). In the 
absence of data on Indians, our study not only reports an association of increased systemic 
levels of BPA in patients with T2DM but also provides preliminary data on association 
among elevated BPA levels, poor glycemic control, insulin resistance, accelerated senescence 
and telomere shortening in patients with T2DM. 
Cellular senescence is characterized by irreversible replicative arrest, apoptosis resistance, 
and frequent acquisition of a pro-inflammatory, tissue-destructive senescence-associated 
secretory phenotype (SASP) (Kirkland & Tchkonia, 2017). In our study, several senescence 
markers (GLB1, p16, p21, p53) at their transcriptional state were seen increased and 
correlated positively to the elevated BPA levels in patients with T2DM. The fact that cells 
from patients with T2DM also exhibited increased gene expression of inflammatory markers 
(TNF-α and IL-6) reflects that these cells acquired SASP status. As previous studies have 
demonstrated an induction of DNA damage, senescence and epigenetic changes by BPA 
exposure (Qin et al., 2012; Ribeiro-Varandas et al., 2014; Jalal et al., 2017), our study 
suggests that studying the link between BPA and SASP should be a priority in the prevention 
as well as management aspects of metabolic disorders including T2DM. 
It has been reported from in vivo and in vitro studies that BPA exerts its disrupting effects on 
the classical nuclear receptors as well as non-classical types so as to mediate metabolic 
dysfunction (Alonso-Magdalena et al., 2012). Among the gene expression patterns of ERs 
and ERRs profiled in our study, most strikingly there was a significant increase in the gene 
expression of ERR-γ in cells from T2DM subjects and it was positively correlated to the 
systemic levels of BPA. This is an important finding in that ERRγ has been identified as an in 
vivo receptor for BPA (Tohmé et al., 2014) and it has been shown to promote hepatic 
gluconeogenesis (Misra et al., 2016) – one of the hallmark pathogenesis of T2DM. While our 
study reports increased gene expression of PPARγ in patients with T2DM, it is important to 
realize that several environmental pollutants including BPA exert their adverse impact on 
adipogenesis and metabolic dysfunction through disturbing the PPAR signalling pathway 
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(Huang & Chen, 2017). Increased gene expression of nucleotide-binding oligomerization 
domain-2 (NOD2) in patients with T2DM seen in our study is also consistent with our 
previous findings (Shiny et al., 2013) and its emerging role in proinflammation (Negroni et 
al., 2018). 
Increased gene expression of CYP2C9 in patients with T2DM compared to NGT individuals 
is an important observation in our study. CYP2C9 is an important enzyme in the liver 
metabolism which is responsible for metabolizing a variety of clinically prescribed drugs 
including anti-diabetic medication (Goldstein & de Morais, 1994). Findings by Xu et al. 
(2017) suggested that BPA exposure has a potential risk of developing adverse health effects 
in human liver metabolism by up regulation of CYP2C9 expression. While diabetic patients 
with variant CYP2C9 genotypes were shown more likely to encounter hypoglycemic adverse 
effects (Holstein et al., 2005), recent findings suggest that CYP2C9*3 genetic variant 
independently contributes to good glycaemic control of patients with T2DM treated with 
glibenclamide (Castelan-Martinez et al., 2018). As variable distribution of CYP2C9 amino 
acid substitution alleles has also been reported in South Indian diabetes patients (Rao et al., 
2017), further studies are needed to unravel the association of increased BPA levels and 
increased CYP2C9 gene expression.  
Our study is of its first-kind to report an association among elevated BPA levels, poor 
glycemic control, insulin resistance, accelerated senescence and telomere shortening in 
patients with T2DM. The decrease in mean telomere length from 1.44 to 1.42 is relatively 
small, but it is statistically significant. Moreover, telomere attrition is a slow 
senescence/ageing related factor and even with the current limitations of the gold-standard 
qPCR evaluation of telomere length, such small differences have been demonstrated to reflect 
biological significance as demonstrated in several studies (Monickaraj et al., 2013; Piplani et 
al., 2018; Sathishkumar et al., 2018). Our pioneering works have unravelled shortened 
telomeres linked to the etiology of T2DM (Adaikalakoteswari et al., 2005; Monickaraj et al., 
2012). Although genetic variants could influence shortening of telomeres in T2DM (Zhou et 
al., 2016), recent studies imply a predominant role by environmental factors. Environmental 
and occupational exposures that include traffic-related air pollution and pesticides were 
reported to induce telomere shortening (Zang et al., 2013; Ziegler et al., 2017). Exposure to 
Persistent Organic Pollutants (POPs) has been earlier shown to predict shortened telomeres in 
the Helsinki Birth Cohort Study (Guzzardi et al., 2016). Very recently, Yuan et al. (2018) 
also observed that the POPs exposure was highly associated with the occurrence of the 
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T2DM, shortened and dysfunctional telomeres with senescence-associated secretary 
phenotype characteristics.  
While there are also reports on the exposure to BPA and gender differences (Caporossi & 
Papaleo, 2015), a recent study reported an association of higher urinary BPA concentrations 
with shortened telomeres in females (Awada et al., 2018). Since the epidemic of T2DM in 
India is also linked to higher prevalence of gestational diabetes mellitus (GDM) 
(Bhavadharini et al., 2016) and the endocrine disruptors have been considered as potential 
risk factors for GDM (Ehrlich et al., 2016), we caution that future studies are warranted to 
expose the BPA-associated gender-specific health burden in women. 
One of the limitations of our study is of its cross-sectional nature. As such we could not 
extrapolate causal link between elevated systemic levels of BPA and T2DM and it needs a 
prospective follow-up study. Moreover, BPA concentrations were only determined in single 
spot serum samples, which may not reflect chronic exposure levels of bisphenols. However, 
some studies have reported that the single spot-sampling approach may adequately reflect an 
average body burden of bisphenols (Ye et al., 2011; Chen et al., 2016). It is suggested that 
future studies should also examine BPA levels in individuals with prediabetes (ie. individuals 
with impaired glucose tolerance, IGT) in order to infer and determine whether elevated BPA 
levels could predate and play a role in the genesis of diabetes. The strength of the study is 
that for the first-time in a clinical diabetes setting, our study provides a directionality of 
elevated BPA levels and accelerated senescence (ageing) in patients with T2DM. BPA 
exposure has been linked to accelerated aging process in the nematode Caenorhabditis 
elegans (Tan et al., 2015) and several cellular stress signalling pathways including increased 
senescence has been demonstrated in human fetal lung fibroblasts on exposure to BPA 
(Mahemuti et al., 2018). As one of the characteristics of Asian Indian Phenotype is early 
onset T2DM (Shah & Mohan, 2015), future studies should focus on the role of BPA as an 
important environmental contributor to the accelerated aging mechanisms linked to the 
genesis of diabetes and its complications. 
To conclude, our study is first of its kind to report an association among elevated BPA levels, 
poor glycemic control, insulin resistance, accelerated senescence and telomere shortening in 
patients with type 2 diabetes.  
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                                         Chapter 3 
Bisphenol A exposure under metabolic stress induces 
cellular senescence in vivo in a p53 independent manner 
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3.1   Abstract 
Senescence or accelerated ageing is an irreversible process that is a characteristic of age- 
associated diseases like Type 2 diabetes (T2DM). This process of accelerated ageing can be 
initiated or enhanced by other external stimuli such as stress or environmental contaminants 
like Bisphenol-A (BPA). BPA, one of the most common endocrine disruptor chemicals, 
received special attention in the development of insulin resistance and T2DM. However, the 
causal mechanisms are not clearly understood. For better understanding of the causal 
mechanisms of BPA, zebrafish embryos were treated with BPA in the absence and presence 
of metabolic stress (hyperglycaemia) condition. Interestingly, the increase in glucose levels 
seen in zebrafish embryos under hyperglycaemia was significantly augmented in the presence 
of BPA. Transcriptional levels of senescence markers such as p15, p53, Rb1 and β-
galactosidase (β-gal) were increased in combination of metabolic stress and BPA exposure, 
and this was also supported by β-gal enzyme expression patterns. In addition, embryos 
exposed to hyperglycaemia and BPA also exhibited increased apoptosis as evident from 
acridine orange and cleaved caspase-3 antibody staining. The fact that senescent markers 
were elevated even in p53 knockdown conditions suggests that senescence might majorly 
involve p15-Rb1 pathway when embryos were treated with metabolic stress coupled to BPA 
exposure. Our work exposes a novel and unique converging role of senescence and apoptosis 
axis contributing to glucose dyshomeostasis. Altogether, we conclude that BPA adds up to 
the existing metabolic stress which induces increased senescence that leads to aggravation of 
disease phenotype in age-associated diseases like T2DM.  
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3.2   Introduction 
In the previous chapters, we discussed about the environmental disruptor chemicals and their 
role in incidence and progression of metabolic diseases such as diabetes. Among them 
Bisphenol A (BPA), a known xenoestrogen has been reported to be associated with the 
pathophysiology of metabolic disorders, especially diabetes (Fang et al., 2015; Provvisiero et 
al., 2016). Diabetes is an age-associated disorder in which cellular senescence plays a 
prominent role in disease progression (Palmer et al., 2015). Studies have shown that 
metabolic stress such as high glucose treatment is capable of inducing stress induced pre-
mature senescence (SIPS) (Park et al., 2014; Kong et al., 2015; Maeda et al., 2015).  
Epidemiological evidences have implied a positive association of BPA with insulin resistance 
(Savastano et al., 2015; Menale et al., 2017; Hong et al., 2017) and in vivo studies have 
shown that BPA is capable of disrupting β-cell function, insulin signalling and cause insulin 
resistance (Alonso-Magdalena et al., 2006; Batista et al., 2012).  
On the other hand, few studies have linked BPA with cellular senescence. p16INK4a   or p16 is 
an inhibitor of Cyclin dependent kinase 4 and 6 (CDK4/6) resulting in cell cycle arrest 
(Narita et al., 2003) leading to senescence. In a study by Qin et al. (2012), human mammary 
epithelial cells (HMEC) that were exposed to BPA showed increased levels of p16 protein 
which induced cellular senescence. Gestational BPA exposure in animal studies has been 
linked to pancreatic β-cell senescence in mothers post-delivery as evident from increased 
expression of p16 and p53 along with enhanced apoptosis, which were associated with 
pancreatic β-cell dysfunction (Alonso-Magdalenaet al., 2015). Further, the study also showed 
that BPA can induce epigenetic alterations leading to senescence. Tan et al. (2015) studied 
the effects of BPA on C. elegans and suggested that the animal on exposure to BPA 
generated ROS and superoxide anions creating oxidative stress condition, which resulted in 
accelerated aging.   
Apart from these limited works, there was no proper scientific evidence for the effect of BPA 
on accelerated senescence and its causative mechanism under the influence of metabolic 
stress, especially in an in vivo model organism.  
Therefore, the aim of this chapter is to study the effect of high glucose-induced senescence 
changes to see whether that could be augmented by external environmental contaminant like 
BPA. The study utilized zebrafish as an in vivo model.  
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Zebrafish is an established model organism to study development and to model human 
diseases (Kari et al., 2007; Veldman & Lin, 2008). In recent years, it is increasingly 
becoming a suitable model organism to study metabolic anomalies. In fact, zebrafish is a 
good model organism to study metabolism as it possesses all the key organs involved in 
energy homeostasis similar to human in addition to the advantages like easy handling, being 
cost effective, high fecundity rate and lesser life span (Elo et al., 2007; Seth et al., 2013).  
This study holds importance in this context, as this is the first unique study highlighting the 
impact of BPA on the process of accelerated ageing under the influence of metabolic stress in 
zebrafish (Danio rerio) as an in vivo model.  
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3.3   Methodology 
3.3.1   Ethical Statement 
Animal ethics approval was obtained from Deakin University animal welfare committee in 
accordance with national guidelines: AWC: G17-2015.  
3.3.2   Chemical Treatment 
Zebrafish embryos were collected and maintained in E3 media at 28°C. Embryos were 
treated with 100 nM BPA (Catalog#239658, Sigma), 2.5% of high glucose condition, 
combination of 100 nM BPA and high glucose and DMSO only as a control. 500 nM 
reactivation of p53 and induction of tumour cell apoptosis (RITA) (Catalog#213261-59-7, 
Cayman chemicals) was used as a positive control. All the treatments were done from 3 days 
post fertilization (3dpf) to 6 days post fertilization (6dpf) (Figure 1). At the end of day 6, 
experiments were carried out. For those experiments involving staining, de-pigmentation was 
carried out by treatment by phenylthiourea (PTU), used at concentration of 1:100 or 
combination of 1% Potassium hydroxide & 3% Hydrogen peroxide for an hour at room 
temperature.   
 
 
Figure 1: Illustration depicting treatment timings: 100 nM BPA and 2.5% high glucose 
treatments were carried out from day 3 to day 6 of post fertilization. RITA was treated in the 
last 12 hours of day 6.  
 
3.3.3   Glucose Measurement 
At the end of treatment conditions, embryos were pooled together and E3 media was 
removed, followed by PBS washes. The embryos were then homogenised with electrical 
homogenizer. Resulting suspension was centrifuged and the supernatant was taken for 
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glucose measurement. Whole body glucose measurements were recorded with Accu-Check 
Performa glucose meter.  
3.3.4   RNA isolation and qRT-PCR analysis 
Real-time PCR was used to examine senescence-related mRNA expression. At the end of the 
treatment period, embryos were collected and pooled into groups of 30 and processed for 
RNA isolation using RNeasy Mini Kit (Catalog#74106, QIAGEN). cDNA was synthesised 
from RNA using Maxima H Minus First Strand cDNA synthesis kit (Catalog#K1652, 
Thermo Scientific). This was followed by quantitative real-time qRT-PCR assay performed 
using Power SYBR green PCR master mix (Catalog#4367659, Applied Biosystems). 
Detection and analysis were performed in PikoReal 96 Real time PCR machine (Thermo 
Scientific). The amount of single strand DNA (ssDNA) or cDNA concentration was 
determined in the RT samples using a Quant-iTOliGreen ssDNA Assay Kit 
(Catalog#O11492, Invitrogen) as previously described (Lundby et al., 2005). For each 
sample, the amount of a given target cDNA was normalized to the ssDNA content in the 
sample. Gene expression of senescence markers (viz. β-gal, p15, p21, p53, Rb1) were 
analysed. 
3.3.5   Senescence Associated β-galactosidase assay (SA-β-gal) 
Measuring the senescence associated β-galactosidase enzyme (SA-β-gal) activity is 
recognized as a standard procedure for detecting cellular senescence (Dimri et al., 1995). SA-
β-gal assay was performed after the treatment period to analyse the intensity of SA-β-gal 
expression in the zebrafish embryos using Senescence β-galactosidase Staining Kit 
(Catalog#9860, Cell Signaling Technology). Embryos were washed and fixed for at least 4 
hours. It is then followed by addition of β-galactosidase staining solution (pH 6.0) and kept at 
37°C overnight. On the subsequent day, the embryos were stored in 70% glycerol and used 
for imaging under light microscope.  
3.3.6   Acridine Orange staining (Live Imaging) 
Acridine Orange (AO), a nucleic acid-sensitive dye was used to stain and visualize the 
presence of apoptotic cells (Plemel et al., 2017). The cell undergoing apoptosis will produce 
numerous lysosomes (Mrschtik & Ryan, 2015). AO has the tendency to penetrate cell 
membrane and bind to the lysosomes and can also intercalate with the nucleic acid (Mpoke et 
al., 1997; Pierzyńska-Mach et al., 2014). At the end of treatment, embryos were added with 
 66 
 
2.5 µg/mL of AO staining solution in E3 media. This was followed by incubation at room 
temperature for 30 minutes. After incubation, embryos were washed with E3 media. Prior to 
imaging, the embryos were anesthetised with 1X Tricaine, followed by imaging using ZOE 
fluorescent cell imager (BioRad, CA, USA). 
3.3.7   Immunohistochemistry analysis using Anti-Cleaved Caspade-3 antibody staining 
At the end of treatment, embryos were fixed in 4% PFA overnight. Fixing solution was 
removed and the embryos were added with 100% ice-cold methanol and incubated at -20°C 
for 2 hours or overnight. It is then followed by subsequent washes with 1x PDT (1x PBST, 
0.3% Triton-X100, 1% DMSO). Blocking buffer (10% FBS, 2% BSA, 1x PBSTw) was 
added and incubated at room temperature with gentle rocking for an hour. 1µl of rabbit anti-
cleaved (anti-activated) caspase-3 antibody (1:500 dilution) was added. It is then incubated at 
room temperature with gentle rocking for 2 hours or incubated overnight at 4°C. Next, the 
blocking buffer was removed, and tubes are washed with 1xPDT. Blocking buffer step was 
repeated as before but this time with anti-rabbit fluorophore conjugated secondary antibody at 
a concentration of 10 µg/mL. After incubating for 2 hours, the embryos were washed with 1x 
PDT and were ready for imaging. ZOE fluorescent cell imager was used for capturing 
fluorescent images.    
3.3.8   Morpholino Injection 
Antisense morpholino oligonucleotides, obtained from Gene Tools, Inc. (Philomath), for p53 
were injected into the embryos at 1 cell stage of post fertilization. Oligo sequence is given in 
Table 1. 4 nl of 1 mM p53 MO stock was injected with phenol red at 4:1 concentration. 
Treatments were carried out as mentioned before. After appropriate treatment conditions, 
these p53MO+ embryos were used for determining the expression levels of senescence 
markers, which is followed by SA-β-gal assay to determine β-gal enzyme levels following 
the methodology described previously. 
3.3.9   Statistical Analysis 
All bar graphs are drawn using GraphPad Prism 6. Data represent mean ± SEM. The 
statistical significance (*P ≤ 0.05) was determined by One-way ANOVA using GraphPad    
Prism 6.  
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3.4   Results 
3.4.1   Glucose measurement shows the disruption of glucose homeostasis 
One of the criteria to design a study related to high glucose is to ensure that levels of glucose 
are elevated after the high glucose treatment. Initially, we determined the whole-body glucose 
level of zebrafish embryos after treatment with 100 nM BPA. Environmentally relevant dose 
of BPA was determined to be 10-100 nM (Pfeifer et al., 2015). Based on dose response 
treatment for toxicity, with concentrations varying from 10-100 nM BPA, we determined 100 
nM BPA as the optimum for our experiment; as best results in terms of no mortality rate, as 
well as optimal gene expression of senescence markers were achieved in that concentration. 
BPA was combined with and without metabolic stress condition for 3 to 6dpf (days post 
fertilization). Metabolic stress was achieved by treating embryos with 2.5% high glucose. 
After dose response treatment, 2.5% high glucose was chosen for the treatment. Beyond that 
concentration mortality rate was seen increased and there was changes in morphogenesis of 
the embryos. Media with DMSO was used as a vehicle control. 500 nM RITA (reactivation 
of p53 and induction of tumour cell apoptosis) was used as a positive control. Based on 
previous publications (Yang et al., 2009; Ahmed et al., 2011) and dose response treatment to 
check toxicity, 500 nM concentration of RITA was chosen for treatment. 500 nM treatment 
of RITA for 12 hours showed no mortality and no changes in morphogenesis was observed. 
At the end of day 6, glucose measurement was carried out with Accu-Check Performa 
glucose meter. Figure 2A shows the levels of whole-body glucose measurement. Presence of 
metabolic stress was confirmed by the higher levels of whole-body glucose induced by high 
glucose treatment. The combination of high glucose with BPA had a 2.5-fold increase in the 
glucose level compared to high glucose condition. Negligible levels of glucose were present 
in control and BPA and RITA, which was assigned an arbitrary value of 0.6 mmol/L 
according to manufacturer’s protocol. Four-fold increase in the glucose levels of embryos 
treated with combination of BPA with high glucose treatment in comparison with control 
indicates the disruption of glucose metabolism.  
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Figure 2: (A) Whole body glucose measurement done in 6dpf zebrafish embryos treated 
from 3dpf to 6dpf, with DMSO (vehicle control), 2.5% glucose (HG), 100 nM BPA, 
combination treatment of high glucose and BPA (HG+BPA) for 3dpf to 6dpf. 500 nM RITA 
(reactivation of p53 and induction of tumour cell apoptosis) treated for 12 hours at the end of 
treatment period was used as a positive control. Accu-Check Performa glucose meter was 
used to measure glucose levels. Data represented as Mean ± SEM from n=3 independent 
measurement with ≥30 embryos per group.  L0 value is taken as 0.6 mmol/L as per glucose 
meter indications. *p<0.05 vs. Control, #p<0.05 vs. High Glucose, @p<0.05 vs. BPA, 
&p<0.05 vs. BPA + High Glucose.  
(B)-(F) mRNA expression of senescence markers: (B) β-Gal, (C) p15, (D) p21, (E) p53, (F) 
Rb1 in 6dpf zebrafish embryos after appropriate treatment (as mentioned above). Data 
represented as Mean ± SEM from n=3 independent measurement with ≥30 embryos per 
group. *p<0.05 vs. Control, #p<0.05 vs. High Glucose, @p<0.05 vs. BPA, &p<0.05 vs. BPA 
+ High Glucose.  
(G)-(K) Representative images of β-galactosidase enzyme expression pattern in 6dpf 
zebrafish embryos after appropriate treatment (as mentioned above). (G) Control, (H) High 
glucose, (I) BPA, (J) BPA+ High glucose, (K) RITA. Black arrow head indicates the β-gal 
enzyme expression pattern showing the cells undergoing senescence (green marks) localized 
near the ventral blood vessels of the trunk. Scale bar: 50 µm. 
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3.4.2 Transcriptional levels of senescence markers indicate the higher rate of 
accelerated ageing 
Accelerated cellular senescence is observed in people with diabetes (Palmer et al., 2015). 
Senescence-associated genetic signals are shown to be higher in individuals with 
hyperglycaemic condition (Maeda et al., 2015; Stefano et al., 2016). As our study involves 
metabolic stress condition (hyperglycaemia) induced by high glucose, it was necessary for us 
to check the expression of senescence markers such as β-gal (Beta-Galactosidase/glb1), p15, 
p21, p53 and Rb1 (Retinoblastoma-1). Our focus here was on the gene expression pattern of 
senescence markers when BPA was combined with metabolic stress. Embryos after 
appropriate treatment conditions (Figure-1) were utilized to extract RNA, which was then 
converted to cDNA by the enzyme reverse transcriptase. Followed by this qRT-PCR analysis 
was done to determine the gene expression pattern of senescence markers. Figure 2(B-F) 
shows various levels of senescence markers. All the markers associated with senescence are 
seen elevated. β-gal expression in all treatment conditions was significantly higher than in 
control. BPA with high glucose condition was significantly elevated compared to all other 
conditions. As the expression of β-gal is the most important indicator of senescence, our 
results indicate that high glucose and BPA have the potential to cause senescence on their 
own or when combined.  
Similar to β-gal, p53 showed increased expression in all conditions. Interestingly p21, which 
is a downstream signalling molecule of p53 dependent pathway for senescence, is 
significantly lower in BPA with and without high glucose. This may indicate that the 
senescence occurrence is through a p53 independent pathway. The other pathway for 
senescence is p15-Rb pathway. In the p15 expression alone, BPA condition did not show any 
significant difference from control. However, when high glucose is added to the combination, 
it elevates the p15 expression significantly compared to the control. Rb1 gene expression 
pattern was similar to β-gal gene expression where combination of BPA and high glucose 
shows few folds higher expression than control. These results indicate that BPA in 
combination with metabolic stress can possibly increase the intensity of senescence through 
p53 independent, p15-Rb1 associated pathway. All primers used in this study are listed in 
Table 1.    
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Zebrafish Primers Sequence   
β-gal forward primer 5’-ATGGGCAGAATCAACTACGG-3’ 
β-gal reverse primer 5’-CGACACTCAGGGAATACACAG-3’ 
p15 forward primer 5’-CGAGGATGAACTGACCACAGC-3’ 
p15 reverse primer 5’-CAAGAGCCAAAGGTGCGTTAC-3’ 
p21 forward primer 5’-CAAGCCAAGAAGCGTCTAGTG-3’ 
p21 reverse primer 5’-AACGGTGTCGTCTCTGGTTC-3’ 
p53 forward primer 5’-GCGATCATGGATTTAGGCTC-3’ 
p53 reverse primer 5’-CTTATAGATGGCAGTGGCTCG-3’ 
Rb1 forward primer 5’-CTGCTCACCTCACATCCAGA-3’ 
Rb1 reverse primer 5’-ATCCACGTTTTTCACCTTGC-3’ 
p53 MO 5’-GAATTGATTTTGCCGACCTCCTCT-3’ 
 
Table 1 shows the list of primers used for qPCR analysis and p53 morpholino sequence 
used to knockdown p53 expression in zebrafish embryos. 
 
3.4.3   Visualization of senescence associated β-galactosidase in vivo 
Gene expression analysis gave us a hint on the possible mode and intensity of senescence. To 
further confirm this, we performed Senescence Associated β-gal assay (SA-β-gal). β-gal is a 
hydrolytic enzyme that hydrolysis β-galactosides, which is only present in cells undergoing 
senescence (Dimri et al., 1995). Post treatment, embryos were subjected to β-gal assay. 
Figure 2(G-K) shows the expression of β-gal that indicates the intensity of senescence in that 
particular region. Liver (the hotspot of metabolism), the ventral part of the trunk where blood 
vessels are located (arrow) and other regions near the tail showed higher intensity of β-gal 
expression in BPA with high glucose-treated embryos. Treatment with BPA alone did not 
have much difference from control, whereas high glucose treatment alone or in combination 
with BPA showed an intense stain. This assay confirms the presence of senescence and also 
shows the intensity at which senescence is occurring in various parts of the embryo.   
3.4.4   Possibility of dual mechanism involving apoptosis: 
Our gene expression results indicated that senescence is happening in a p53-independent 
pathway. However, we had also shown increase in p53 expression, which indicated the 
possibility of presence of apoptosis. Apoptosis is a factor that occurs in individuals with 
diabetes, especially in the pancreatic β-islet cells, which results in the reduction in number of 
the cells (Anuradha et al., 2014). It is not a surprise that metabolic stress on its own can cause 
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apoptosis, along with senescence. However, in the current study, we have shown that BPA 
along with metabolic stress can also lead to apoptosis simultaneously with senescence.    
Acridine Orange (AO) staining was performed to visualize the presence of apoptotic cells in 
live embryos with using fluorescent microscopy. AO is a fluorescent dye that traverses cell 
membrane and intercalates with nucleic acids and also binds to lysosomes that are present 
abundantly in apoptotic cells (Mpoke et al., 1997). Embryos were treated with the dye prior 
to imaging. This was followed by imaging which was done in ZOE fluorescent cell imager. 
Figure 3(A-E) shows the presence of apoptotic cells in the embryos. BPA in combination 
with high glucose and high glucose alone showed the presence of more apoptotic cells 
compared to the control embryos. BPA alone did not show much change from the control.  
For further re-confirmation on apoptotic process, immunohistochemical analysis using 
Cleaved caspase-3 Antibody staining was performed. Caspases are a family of protease 
enzyme that are involved in apoptosis (Li & Yuan, 2008). Among other caspases, caspase-3, -
6, -7, -8, and -9 are the ones involved in apoptosis (McIlwain et al., 2013). Among these, 
caspase-3 was identified to be the major caspase involved in apoptosis, as it is the primary 
regulator of DNA fragmentation and Poly (ADP-ribose) polymerase (PARP) cleavage which 
are hallmarks of apoptosis (Kiraz et al., 2016). Hence it was important for us to analyze the 
presence of activated caspase-3 which further re-confirms the occurrence of apoptosis. 
Presence of apoptotic cells was imaged with ZOE fluorescent cell imager. Figure 3(F-J) 
shows the inverted image of Cleaved caspase-3 Antibody staining. The results were similar to 
acridine orange staining, where BPA along with high glucose was shown to increase 
apoptosis in comparison to control. These results expose a novel and unique converging role 
of senescence and apoptosis axis contributing to glucose dyshomeostasis. 
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Figure 3: (A)-(E) Representative images of acridine orange staining done in 6dpf 
zebrafish embryos treated from 3dpf to 6dpf, with DMSO (vehicle control), 2.5% glucose 
(HG), 100 nM BPA, combination treatment of high glucose and BPA (HG+BPA) for 3dpf to 
6dpf. 500 nM RITA (reactivation of p53 and induction of tumour cell apoptosis) treated for 
12 hours at the end of treatment period was used as a positive control. Live fluorescent 
imaging of the Zebrafish embryos was done using ZOE live cell imager. (A) Control, (B) 
High glucose, (C) BPA, (D) BPA+ High glucose, (E) RITA. In the images at top, yellow 
arrow head indicates the presence of apoptotic cells (green marks). The images at the bottom 
are bright field images of the embryos in representation figure (above). Scale bar: 50 µm. 
(F)-(J) Representative images of cleaved caspase-3 antibody staining done in 6dpf 
zebrafish embryos after appropriate treatment (as mentioned above). Fluorescent imaging of 
the zebrafish embryos was taken using ZOE live cell imager. (F) Control, (G) High glucose, 
(H) BPA, (I) BPA+ High glucose, (J) RITA. Yellow arrow heads in the inverted images 
above indicate the presence of apoptotic bodies (black marks). The images at the bottom are 
bright field images of the embryos in representation figure (above). Scale bar: 50 µm. 
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3.4.5   Expression of Senescence markers even in the absence of p53  
The purpose of knockdown of p53 is to confirm whether senescence runs unaffected or 
lowered in BPA treated conditions; even in the absence of p53. Knockdown of p53 was 
achieved by targeting morpholino (MO) to p53 mRNA in zebrafish embryos which 
effectively blocks the translation of p53, resulting in lowering p53 protein levels with no 
visible phenotype produced (Duffy & Wickstrom, 2007). Embryos were microinjected with 
p53 MO at single-cell stage that resulted in knockdown of p53 mRNA expression. Embryos 
were then cultured as regularly and treated with appropriate treatment conditions as in 
Figure-1. The embryos were then pooled for RNA extraction and cDNA conversion followed 
by qRT-PCR analysis to determine the expression levels of senescence markers: β-gal, p15 
and Rb1. (Figure 4A-C). Both β-gal and Rb1 gene expression patterns were similar, and this 
indicates that senescence runs uncontrolled even in the absence of p53. High glucose and 
combination of BPA with high glucose have shown significant increase in senescence 
markers compared to the control. Though the expression levels of p15 in combination of BPA 
and high glucose condition had slight increase compared to the control, it was not significant.   
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Figure 4: (A)-(C) mRNA expression of senescence markers: (A) β-Gal, (B) p15, (C) Rb1, 
in zebrafish embryos that are p53 knockdown, achieved by injecting p53 morpholino (p53 
MO+). qRT-PCR was performed after zebrafish embryos were treated from 3dpf to 6dpf, 
with DMSO (vehicle control), 2.5% glucose (HG), 100 nM BPA and combination treatment 
of high glucose and BPA (HG+BPA). Data represented as Mean ± SEM from n=3 
independent measurement with ≥30 embryos per group. *p<0.05 vs. Control, #p<0.05 vs. 
High Glucose, @p<0.05 vs. BPA, &p<0.05 vs. BPA + High Glucose.  
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(D)-(G) Representative images of β-galactosidase enzyme expression pattern in p53 MO+ 
zebrafish embryos (right side images) after appropriate treatment (as mentioned above). (D) 
Control, (E) High glucose, (F) BPA, (G) BPA+ High glucose. The p53 MO+ representation 
images are compared with wild type (p53 MO-) representation image (left side images). 
Black arrow head indicates the β-gal enzyme expression pattern showing the cells undergoing 
senescence (green marks) localized near the ventral blood vessels of the trunk. Scale bar: 50 
µm. 
(H) Magnification of a portion from figure 4 (G). Black arrow head indicates the β-gal 
enzyme expression pattern showing the cells undergoing senescence (green marks) localized 
near the ventral blood vessels of the trunk.   
 
Senescence Associated β-gal assay was also performed to further confirm the results. All the 
p53 MO+ embryos were treated appropriately. SA-β-gal assay was performed following the 
treatment. Figure (4D-G) shows the intensity of β-gal expression in various treatment 
conditions in p53MO+ embryos and was compared with the expression of β-gal in p53 MO- 
embryos. In accordance with gene expression analysis, the result suggests that senescence is 
still occurring even in the absence of p53, though slightly altered. The results suggest that 
senescence happens uncontrolled, though altered in levels, in a p53- independent manner but 
mainly through p15-Rb1 pathway.  
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3.5   Discussion: 
In this study, we have demonstrated that the direct treatment of zebrafish embryos with BPA 
did not alter the senescence levels, which suggests that BPA has no direct effect to increase 
cellular senescence in zebrafish embryos. However, we observed an increase in senescence 
following BPA treatment along with high glucose. This study for the first time showed that 
the combination of BPA and metabolic stress can accelerate senescence process. Few in vitro 
studies have reported an occurrence of cellular senescence in BPA treated cells.  
Initially, the whole-body glucose measurement from 6dpf embryos after appropriate 
treatment conditions was measured. The rise in glucose levels compared to control confirmed 
the establishment of a metabolic stress model. The increased glucose levels in combination of 
BPA and high glucose condition is indicative of the fact that BPA under metabolic stress may 
have the potential to elevate the glucose levels or is capable of causing dyshomeostasis in 
glucose metabolism.  
Studies have shown that metabolic stress like high glucose treatment is capable of inducing 
senescence (Park et al., 2014; Kong et al., 2015; Maeda et al., 2015). On the other hand, 
studies have shown that exposure to BPA can affect glucose homeostasis and lead to glucose 
intolerance and insulin resistance (Moon et al., 2015; Fang et al., 2015). Moghaddam et al. 
(2015) demonstrated in mice model that BPA has the potential to induce hyperglycaemic 
conditions and complications associated with that. In addition to that, Qin et al. (2012) have 
demonstrated that human mammary epithelial cells when exposed to BPA showed a 
remarkable increase in the levels of p16 indicating the occurrence of accelerated cellular 
senescence. However, there is no proper report on the combined effect of BPA and metabolic 
stress on senescence and signalling pathway associated with that. The current study tried to 
address the same.    
SA-β-gal assay measuring the activity of a lysosomal β-galactosidase is a prominent marker 
for detecting senescence (Severino et al., 2000; Wagner et al., 2015; Piechota et al., 2016). In 
our study, both the β-gal gene expression and SA-β-gal enzyme activity are shown to increase 
in high glucose and combination of BPA and high glucose conditions compared to vehicle 
control. Interestingly, BPA on its own showed significant increase over control but lesser 
than high glucose and combination treatment. All together, BPA when combined with 
metabolic stress significantly increased senescence compared to other individual treatments. 
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Now that, we had established the presence of senescence, the molecular pathway underlying 
it has to be established.  
The molecular mechanism of cellular senescence involves p16 and p53 mediated pathways 
(Jacobs & de Lange., 2004; Lee at al., 2014). p15 (cdkn2a/b) in fish, which is similar in 
function to p16 (cdkn2a) in higher organisms, is one of the major proteins involved in cell 
cycle regulation. It binds and inhibits the action of cyclin-dependant kinases 4/6, thereby 
preventing the phosphorylation of Retinoblastoma (Rb1). Rb1 remains associated with 
transcriptional factor E2F1 preventing the transcription of genes necessary for G1 to S phase 
progression of cell cycle. This leads to cell cycle arrest and senescence (Rayess et al., 2011).  
Our in vivo results show that p15 levels significantly increased when BPA combined with 
high glucose compared to control. Higher p15 expression in high glucose compared to control 
was in accordance with previous studies (Maeda et al., 2015; Zhang et al., 2015). Rb1 levels 
were significantly elevated in combination treatment compared to either BPA or high glucose 
alone. This shows that BPA along with metabolic stress may induce senescence through p15-
Rb1 pathway in zebrafish.  
The other major pathway for senescence is p53 dependent. p53, as a transcription factor 
activates downstream effector genes, which includes p21 (Sullivan et al., 2018). p21 inhibits 
activity of various cyclin-dependent kinase complexes (CDK1, CDK2, and CDK4/6), 
mediating p53 dependant G1 growth arrest (Deng et al., 1995; Abbas & Dutta., 2009). A 
study by Kitada et al. (2014) in mice model, reported that during early stages of diabetic 
nephropathy, hyperglycaemia causes cellular senescence by p21-dependent pathway. In our 
study, though significant increase in the level of p53 was seen in combination treatment, 
whereas p21 showed significantly reduced levels compared to control. This suggests that 
BPA when combined with metabolic stress aggravates senescence in a p53 independent 
pathway.  
Rodriguez and Meuth. (2006) through their experiment with human colon cancer cell lines 
demonstrated that, during unfavourable conditions, cells undergo p21-mediated cell cycle 
arrest, preventing it from entering into S-phase. It is transient and once the damage is 
successfully repaired, the cells may resume the cell cycle. However, prolonged cell cycle 
arrest leads to up-regulation of p16 gene expression that further leads to permanent cell cycle 
arrest (Childs et al., 2014). Result from our gene expression analysis suggests that, p15 gene 
expression was up-regulated in the treatment condition involving BPA with high glucose and 
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high glucose alone condition, which indicates that the embryonic cells were under permanent 
cell cycle arrest followed by accelerated senescence.   
The increase in p53 and reduction in p21 expression suggested that there may be a possibility 
of apoptotic pathway simultaneously happening along with senescence. To validate this, our 
study utilized acridine orange (AO) staining of the embryos. AO is a cell-permeant 
fluorescence dye used for staining acidic vesicles such as lysosomes and can bind to nucleic 
acids. It emits green fluorescence if intercalated with double stranded DNA and with single 
stranded RNA it emits red fluorescence (Osman et al., 2018). Normal cells produce light 
green fluorescence, whereas early apoptotic cells produce bright green fluorescence due to 
the presence of fragmented chromatin and late apoptotic cells produce orange fluorescence 
(Ribble et al., 2005). Our results from live imaging showed green fluorescent cells implying 
the presence of early apoptotic cells. The apoptotic cell number was seen increased in both 
high glucose and combination of BPA with high glucose conditions.  
Immunohistochemical analysis by cleaved caspase-3 Antibody staining of zebrafish embryos 
was carried out to re-confirm the presence of apoptotic cells. The results were similar to 
acridine orange staining assay where BPA in combination with high glucose increased 
apoptotic bodies. These results suggest that BPA under the influence of metabolic stress like 
high glucose is capable of aggravating both senescence and apoptosis simultaneously. Chen 
and Liu. (2000) through their experiments, subjected normal human fibroblast cells to 
external stress factor and showed that the cells that undergo apoptosis were distributed 
mainly in S-phase of the cell cycle, whereas cells undergoing senescence were predominantly 
seen in G1/G2 phase of the cell cycle. Our result suggests that the apoptotic cells were 
majorly seen in dorsal side of the head region of the embryos (Figure 3). Whereas, β-gal 
assay reveals that, cells that undergo senescence were majorly localized near the ventral 
blood vessels of the trunk region (Figure 2). It is quite possible that ventral blood vessel cells 
were in G1 phase, whereas the cells near the dorsal head region were in S-phase of the cell 
cycle. Gene expression analysis may not reveal the exact detail of the cellular status under 
stress conditions, tissue region wise, as we utilized whole embryo for gene expression 
analysis. In future study, it is necessary for us to analyze the gene expression in various tissue 
regions in the embryo which will help us to understand the tissue specific effect of BPA.  
The last part of our study focused on re-establishing our finding that accelerated senescence 
happens in embryos treated with BPA under metabolic stress condition through p15-Rb1, 
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independent of p53 pathway. As there was increased p53 expression in combination of BPA 
and high glucose and high glucose alone condition (Figure 2), it was necessary for us to 
determine whether p53 knockdown affects senescence induced by BPA and metabolic stress 
conditions. To achieve this, p53 morpholino was used to silence the p53 gene expression. 
Even after p53 knockdown, the expression levels of senescence markers like β-Gal and Rb1 
significantly increased in combination of high glucose and BPA or high glucose alone 
condition compared to control. SA-β-gal assay re-confirms the presence of senescence, which 
remains unaltered even in the absence of p53. This experiment proves that silencing p53 does 
not affect senescence mechanism and further goes on to show that BPA along with metabolic 
stress aggravates senescence in p53 independent manner. As p53 inhibition did not block the 
senescence-induction effects of BPA, it was suggested that p15 pathway could be a central 
mechanism contributing to the accelerated senescence effects of BPA. However, the correct 
interpretation of the senescence data would require functional analysis of p15. 
 
 
Figure 5: Schematic representation of major outcomes of the study. BPA along with 
metabolic stress induces senescence in p53-independent pathway through p15-Rb1. This was 
confirmed when senescence occurs unaffected even in the absence of p53 expression.  
 
Major outcomes of our study are highlighted in figure 5. It precisely describes the action of 
BPA with and without metabolic stress condition. Cells under the metabolic stress conditions 
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may either lead to senescence through p15-Rb1/p53-p21 pathway or may lead to apoptosis 
through p53 pathway. But when metabolic stress combines with BPA, both apoptosis and 
senescence happen simultaneously, in which senescence happens through p15-Rb1 pathway. 
Also, p53 knockdown experiment shows that senescence runs unaffected even in the absence 
of p53.  
In conclusion, this study for the first time has shown in a vertebrate model that BPA in 
combination with metabolic stress like high glucose has the potential to aggravate the 
senescence in p53 independent manner and majorly through p15-Rb1 pathway. The study 
also reveals that BPA along with metabolic stress may lead to apoptosis coupled to 
senescence simultaneously and the mechanisms or signals that lies as a thin line between 
these two processes has to be well studied in future.  
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                                         Chapter 4 
Bisphenol A exposure under metabolic stress induces    
cellular senescence and impairs glucose uptake in skeletal   
muscle cells 
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4.1   Abstract 
Cellular senescence is an irreversible process that is commonly seen in age-associated 
diseases like Type 2 diabetes (T2DM). Bisphenol A (BPA), an endocrine disruptor, is known 
to be associated with metabolic anomalies like diabetes. The mechanism by which BPA 
impacts the diabetes pathogenesis is still unclear. While there is lack of studies to 
demonstrate the potential of BPA to cause cellular senescence, hardly any studies have 
focused on the impact of BPA on insulin-target tissues under metabolic stress condition. The 
mechanism by which BPA aggravates the pathogenesis of diabetes is still unknown. Through 
our clinical and in vivo studies, we deciphered that BPA under metabolic stress induces 
accelerated senescence through p16 pathway, which may further lead to aggravation of 
disease pathogenesis. However, this mechanism has to be demonstrated in metabolically 
active target cell models, which are responsible for glucose metabolism and homeostasis. Our 
study utilized skeletal muscle cells for this purpose. Skeletal muscle comprises of 
metabolically active cells which are essential for glucose regulation and maintenance in our 
body. The results obtained were consistent with our in vivo study, wherein senescence 
occurred through p16 pathway, independent of p53. In addition to this, deterioration of 
insulin stimulated glucose uptake and reduction in GLUT-4 protein expression were 
witnessed. Altogether, we conclude that BPA adds up to the existing metabolic stress, which 
induces increased senescence along with reduction in insulin-stimulated glucose uptake, 
further leading to the aggravation of the pathogenesis of diabetes.  
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4.2   Introduction 
In previous chapters, we reported that BPA was associated with increased senescence 
markers in diabetic patients. In vivo results also demonstrated that BPA induces accelerated 
senescence under metabolic stress conditions through p15/p16-Rb1 axis. The causative 
mechanism has to be confirmed in a metabolically active insulin target tissue and this form 
the premise for this chapter.  
Skeletal muscles are primary insulin-sensitive metabolic tissues that play an important role in 
glucose regulation and maintenance (Stump et al., 2006). Contracting skeletal muscles 
requires more glucose and hence it uptakes glucose through insulin stimulation, which helps 
in maintaining the glucose levels in circulation (Fritsche et al., 2008). This insulin-stimulated 
glucose uptake happens through glucose transporter-4 (GLUT-4), which translocates into the 
plasma membrane with the help of intracellular signalling mechanism involving insulin 
receptors and Akt-phosphorylation (Saltiel & Kahn, 2001; Satoh, 2014).  
Defective insulin-stimulated glucose uptake in skeletal muscle is the hallmark pathogenesis 
in patients with T2DM (Abdul-Ghani & DeFronzo, 2010). Insulin resistance in skeletal 
muscles is considered to be the primary defect in T2DM patients (DeFronzo & Tripathy, 
2009). Hence, it becomes important for us to confirm our previous findings in skeletal muscle 
cells.  
Only few studies have reported that BPA induces cellular senescence. Two separate studies 
by Indumathi et al. (2013) and Mullainadhan et al. (2017) showed that BPA exposure in 
animal model can affect GLUT-4 translocation and leads to deregulation of insulin stimulated 
glucose uptake process. However, the effect of BPA in metabolic tissues under the influence 
of metabolic stress has not been studied in the background of senescence mechanism.     
Therefore, the aim of this chapter is to confirm our clinical and in vivo animal model findings 
in an in vitro skeletal muscle cell model with a focus on the effect of BPA on senescence and 
insulin-stimulated glucose uptake.  
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4.3   Methodology 
4.3.1   Cell culture treatment 
C2C12, an immortalized mouse myoblast cell line, with passage number 14-19 was used for 
the experiments. Cells were maintained in low glucose (5 mM) DMEM containing 10% FBS. 
The cells were treated with 100 nM BPA. The concentration was selected based on the 
concentration used in zebrafish experiment. Moreover, environmentally relevant dose of BPA 
was determined to be 10-100 nM (Pfeifer et al., 2015).  Based on previous studies on C2C12, 
25 mM glucose condition was determined to be high glucose condition (Hanke et al., 2011; 
Leontieva et al., 2014) and the same was used in our treatment condition. Along with separate 
BPA and high glucose conditions, a combination of 100 nM BPA with high glucose was used 
as one of the conditions. 1 µM reactivation of p53 and induction of tumour cell apoptosis 
(RITA) was used as a positive control. Based on MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 
diphenyl tetrazolium bromide) assay treatment concentration of RITA was fixed; where the 
concentration beyond 1 µM decreased the cell viability. The MTT assay determines 
mitochondrial activity in the cell. MTT gets converted into formazan crystals in the living 
cells which determine the total number of viable cells present in the culture dish (van 
Meerloo et al., 2011). High glucose used in the treatment conditions was provided as a 
glucose excursion, wherein alternate high and low glucose was supplied, mimicking the 
glycemic excursions seen in diabetes patients (Hezarkhani et al., 2013; Fujimoto et al., 2018). 
All the treatments were carried out for 48 hours and, at the end of treatment, cells were 
harvested and processed for further experiments.  
4.3.2   RNA isolation and real-time PCR analysis 
After different experimental manoeuvre, cells were harvested and processed for real-time 
PCR. Total RNA from tissues were isolated as described previously (Balasubramanyam et 
al., 2011). The quality of the RNA and its concentration was measured using NanoDrop 2000 
(Thermo Scientific). First strand cDNA was synthesized using 1 µg of total RNA, 40 µM 
Oligo-d(T)18 primer (Catalog#S13168, New England Biolabs), 2.5 mM dNTPs, 10xRT 
buffer, 20 U RNase inhibitor and 100 units reverse transcriptase enzyme. The resultant mix 
was subjected to 1 hour of incubation at 42˚C, followed by 95˚C for 5 minutes. Real-time 
PCR was performed for senescence-associated genes: β-gal (glb1), p16, p21, p53 and 
retinoblastoma (Rb1) using SYBR green master mix (Cat #F416S Dynamo Color flash Sybr 
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Green QPCR Kit). Amplification was carried out using LC-96 (Light cycler 96, Roche cycle) 
and normalized using endogenous β-actin.  
4.3.3   Quantitative assay of β-Gal activity 
β-galactosidase activity in skeletal muscle cells was measured by performing a fluorometric 
assay following a modified version of the methodology previously described (Spazzafumo et 
al., 2017). Protein was extracted and quantified using BCA kit. 1 mM 4-Methyl-umbelliferyl-
β-D-galactopyranoside in citrate-phosphate buffer (pH 4.0) was used as a substrate. 20 µg of 
protein was incubated with 200 µl substrate for 1 hour at 37°C. The reaction was stopped by 
1 ml of glycine-carbonate buffer. The fluorescence liberated by 4-Methylumbelliferone was 
captured on EnSpire Multimode Plate Reader (PerkinElmer) at excitation wavelength of 360 
nm and at emission wavelength of 446 nm. The enzymatic activity of β-gal was expressed in 
relative frequency units (RFU).  
4.3.4   Western blot protein expression 
Protein lysates from C2C12 cells were prepared using RIPA Lysis and Extraction Buffer 
(Catalog#89900, Thermo Scientific) containing 1X protease inhibitor cocktail 
(Catalog#P8340, SIGMA). Cells were sonicated and incubated for at least an hour in ice, 
followed by centrifugation at 13000 rpm for 30 mins at 4°C. The supernatant was used to 
quantify the protein content using Pierce™ BCA Protein Assay Kit (Catalog#23225, Thermo 
Scientific). 30 µg of protein was resolved on 10% and 12% SDS-PAGE and transferred to 
polyvinylidene fluoride (PVDF) membrane. After an hour of blocking in 5% bovine serum 
albumin (BSA), the membrane was probed with the following antibodies in 1% BSA in 
Phospho-buffered saline with 0.5% Tween 20 (PBS-T): anti-p16 (Catalog#sc-81156, Santa 
Cruz), anti-p21 (Catalog#sc-6246, Santa Cruz) and anti-p53 (Catalog#ab31333, Abcam). A 
mouse anti-β-actin antibody (Catalog#sc-47778, Santa Cruz) was used as an internal control 
for loading. It was then followed by exposure to HRP-conjugated secondary antibodies: anti-
mouse IgG HRP Conjugate (Catalog#A4416, SIGMA) and goat anti-rabbit IgG HRP 
Conjugate (Catalog#A6154, SIGMA). Detection was performed using enhanced 
chemiluminescence kit (GE Healthcare) and blots were quantified using Image-J software. 
Protein of interest was normalized using β-actin.  
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4.3.5   Glucose uptake assay 
2-(N-(7-Nitrobenz-2-oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG) was used as a 
marker for detecting insulin stimulated glucose uptake (Chen et al., 2015). Myogenic 
differentiation of C2C12 cells was induced by changing the growth medium to differentiation 
medium, which was supplemented with 2% FBS for 4 days. Treatment protocol as mentioned 
earlier was carried out in the last 48 hours of differentiation period. Myotubes were then 
washed with PBS and kept for starving in DMEM containing no glucose for 3 hours at 37°C. 
Cells were then shifted to Hepes buffer containing 0.5% BSA with no glucose. The cells were 
then incubated with 100 nM insulin for 30 mins followed by treatment with 60 µM 2-NBDG 
(Catalog#N13195, Thermo Scietific) for an hour at 37°C. Total amount of 2-NBDG 
incorporated into the cells was measured in cell lysates by fluorescence. The fluorescence 
read-out was measured using EnSpire Multimode Plate Reader (PerkinElmer) at excitation 
wavelength of 485 nm and emission wavelength of 535 nm. Final fluorescence readings were 
represented as percentage (%) insulin stimulated glucose uptake. 
4.3.6   Statistical Analysis 
All bar graphs are drawn using GraphPad Prism 6. Data represent mean ± SEM. The 
statistical significance (*P ≤ 0.05) was determined by One-way ANOVA using GraphPad 
Prism 6. 
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4.4   Results 
4.4.1 Elevation of senescence markers in skeletal muscle cells under treatment       
conditions 
Transcriptional levels of senescence markers were quantified using real-time PCR. mRNA 
expression of senescence markers- β-gal, p16, p21, p53 and Rb1 was analysed (Figure 1A-
E). β-gal and Rb1 expressions in all treatment conditions were higher than control, and 
significant elevation was seen in combination of BPA and high glucose conditions compared 
to control. Both β-gal and Rb1 showed approximately (~) 1.25 fold increase compared to 
control. p16 was equally elevated in both high glucose and combination treatment. p16 
expression was ~1.6 fold higher in high glucose condition compared to control. Combination 
of BPA and high glucose treatment showed ~2 fold increase compared to the control. p53 and 
p21 mRNA expressions in individual treatments of high glucose and BPA showed slight 
increase compared to control. However, in combination treatment, no significant increase was 
observed. This shows that, BPA when combined with metabolic stress follows p16 pathway 
to cause senescence, which is independent of p53 pathway. These results were consistent 
with our findings obtained in in vivo model (Chapter 3). List of primers used in this study was 
given in Table 1. 
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Figure 1: (A)-(E) mRNA expression of senescence markers: (A) β-gal, (B) p16, (C) p21, 
(D) p53, (E) Rb1 in C2C12 myoblast cells. Treatment condition includes control, 25 mM 
glucose (HG), 100 nM BPA and combination treatment of high glucose and BPA 
(HG+BPA). High glucose was provided as glucose excursion, wherein alternate high and low 
glucose was provided every 12 hours. 1 µM RITA (reactivation of p53 and induction of 
tumour cell apoptosis) was used as a positive control. All the experiments are repeated 
individually at least thrice. Data represented as Mean ± SEM. *p<0.05 vs. Control, #p<0.05 
vs. High Glucose, @p<0.05 vs. BPA, &p<0.05 vs. BPA+ High Glucose.  
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Mouse Primers   
β-gal forward primer 5’-GTGAAAAGCCTCTATCCCCTG-3’ 
β-gal reverse primer 5’-ATCACGGACACCATTGAAGG-3’ 
p16 forward primer 5’-CGCCTTTTTCTTCTTAGCTTCA-3’ 
p16 reverse primer 5’-AGTTTCTCATGCCATTCCTTTC-3’ 
p21 forward primer 5’-CTTGCACTCTGGTGTCTGAG-3’ 
p21 reverse primer 5’-GCACTTCAGGGTTTTCTCTTG-3’ 
p53 forward primer 5’-ATGTTCCGGGAGCTGAATG-3’ 
p53 reverse primer 5’-CCCCACTTTCTTGACCATTG-3’ 
Rb1 forward primer 5’-CAGGCTTGAGTTTGAAGAAATTG-3’ 
Rb1 reverse primer 5’-ATGCCCCAGAGTTCCTTCTTC-3’ 
 
Table 1 showing the list of primers used in this study for real-time PCR.  
 
4.4.2   β-Galactosidase activity assay shows significant increase in BPA-treated and 
combination treatment 
Quantitative assay of β-gal activity showed significant increase in β-gal activity in all three 
conditions compared to control (Figure 2). BPA and BPA in combination with high glucose 
were also significantly elevated compared to high glucose alone condition. This suggests that 
BPA individually has the potential to raise the senescence level; in addition, when combined 
with high glucose induces even more senescence in the skeletal muscle cells.    
 
                                             
 90 
 
  
Figure 2: Quantitative assay of β-gal activity: β-galactosidase activity evaluated in C2C12 
myoblast cells after appropriate treatment (as mentioned above). β-galactosidase activity was 
reported as Relative Frequency Units (RFU). Data represented as Mean ± SD. All the 
experiments are repeated individually at least thrice. *p<0.05 vs. Control, #p<0.05 vs. High 
Glucose, @p<0.05 vs. BPA. 
 
4.4.3   Western blot analysis confirms the elevated levels of senescence markers 
Western blot analysis for senescence markers showed significantly higher protein levels of 
p16 and p53 in BPA treated condition compared to control (Figure 3). Apart from BPA 
treatment, other treatments showed no significant increase in p53 protein levels compared to 
control. The increase in p53 protein expression in BPA treated was similar to the gene 
expression result. However, unlike in gene expression, p21 protein expression in BPA treated 
cells did not show any significant difference, that in turn indicates the presence of apoptosis. 
Previously, in our in vivo study (Chapter 3), we had already showed that BPA might be 
capable of inducing both senescence and apoptosis simultaneously. There was a significant 
increase in p16 expression in all the other treatments compared to control. C2C12 cells 
treated with BPA showed a significant increase in p16 protein expression, although it was not 
similarly reflected in p16 gene expression. The difference could be due to BPA impacting on 
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post-transcriptional regulation, such as translation or protein stability, allowing greater p16 
levels despite no change in p16 mRNA (Li et al., 2011). Alternatively, it could be related to 
protein expression related feed-back mechanism potentially involving miRNA(s) that might 
return a transient increase in p16 mRNA back to normal levels (Overhoff et al., 2014). Only 
high glucose was shown to significantly increase p21 expression.  
 
 
Figure 3: (A) Representative images of western blot analysis of p16, p21 and p53 in 
C2C12 myoblast cells. Treatment condition includes control, 25 mM glucose (HG), 100 nM 
BPA and combination treatment of high glucose and BPA (HG+BPA). High glucose was 
provided as glucose excursion, wherein alternate high and low glucose was provided every 12 
hours. 1 µM RITA was used as a positive control. β-ACTIN was used as internal control.  
(B) Relative protein levels of p16, p21 and p53. All the experiments are repeated 
individually at least thrice. Data represented as Mean ± SEM. *p<0.05 vs. Control. 
 
4.4.4    2-NBDG assay reveals the impact of BPA on insulin stimulated glucose uptake 
2-NBDG glucose uptake assay shows difference in insulin stimulated glucose uptake in cells 
subjected to different treatments (Figure 4). All the treatment groups showed significant 
reduction in glucose uptake compared to control. Comparatively, BPA treated condition 
showed marked decrease in glucose uptake compared to both control and high glucose. These 
results imply that BPA in combination with high glucose or BPA alone has the potential to 
disrupt glucose uptake potential of the cells.   
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Figure 4: 2-NBDG glucose uptake assay showing percentage change in insulin-stimulated 
glucose uptake between treatment groups: Control, HG-High Glucose, BPA, combination 
treatment of (BPA+HG) and RITA. All the experiments are repeated individually at least 
thrice.  Data represented as Mean ± SEM. *p<0.05 vs. Control and #p<0.05 vs. High glucose. 
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4.4.5 GLUT-4 protein expression supports the impact of BPA on reduced glucose 
uptake 
Translational analysis of GLUT-4 protein showed significant decrease in the combination 
treatment of BPA and high glucose (Figure 5). Decreasing trend was observed in the 
individual treatments though it was not significant. This confirms that BPA along with high 
glucose may impair glucose transporter, subsequently leading to poor glucose uptake in 
skeletal muscle cells. 
 
Figure 5: (A) Representative images of western blot analysis of GLUT-4 in C2C12 
myoblast cells. Treatment condition includes control, 25 mM glucose (HG), 100 nM BPA 
and combination treatment of high glucose and BPA (HG+BPA). High glucose was provided 
as glucose excursion, wherein alternate high and low glucose was provided every 12 hours.   
1 µM RITA was used as a positive control. β-ACTIN was used as internal control. (B) 
Relative protein levels of GLUT-4. All the experiments are repeated individually at least 
thrice. Data represented as Mean ± SEM. *p<0.05 vs. Control. 
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4.5   Discussion 
Cellular senescence was reported as a cause and consequence of T2DM (Testa & Ceriell., 
2007). This was also inferred from our clinical and zebrafish animal model studies. Hence it 
was necessary for us to replicate our in vivo results in a metabolic tissue model like skeletal 
muscle cells. Skeletal muscle cells are metabolically active (Slentz et al., 2009). 
Transcriptional regulation of genes involved in glucose metabolism was reported in muscle 
tissues (Baskin et al., 2015). It is the major insulin-sensitive tissue in our body that induces 
insulin-stimulated glucose uptake (Stump et al., 2006). In order to maintain proper blood 
glucose levels in circulation, insulin promotes glucose utilization in muscle cells, thus 
inhibiting hepatic gluconeogenesis (Fritsche et al., 2008). Our study utilized C2C12, an 
immortalized mouse myoblast cell line. 
The results from cell culture study were consistent with animal model aberrations, where β-
gal gene expression was significantly increased in the combination of BPA and high glucose 
condition. Accumulation of β-gal expression is an indicator of cells undergoing senescence 
(Wagner et al., 2015). In our study, β-gal gene expression was significantly higher in the 
combination treatment condition of BPA and high glucose compared to control. This shows 
that the level of senescence is highly influenced by BPA especially when it combines with 
metabolic stress. In addition to this, β-galactosidase activity assay (Figure 2), in which the 
activity of the β-gal protein is measured, also confirmed the presence of increased senescence 
in the combination treatment.  
In the in vivo study in zebrafish, we observed that senescence happened through the p15-Rb1 
axis. Here we analysed the levels of p16 which is the mammalian ortholog of p15, which are 
similar in biochemical properties and function (Li et al., 2011), as p16 is considered to be a 
robust biomarker for prediction of cellular ageing (Ressler et al., 2006; Dimri 2004, Sharpless 
& DePinho 2007). Our study found a significant increase in the p16 and Rb1 gene expression 
levels.  
Cyclin dependent kinase 4 and 6 (CDK4/6) negatively regulates Rb1 (Tang et al., 2012) and 
these kinases are inhibited by cyclin-dependent kinase inhibitors such as p16 and p21 which 
initiates senescence (Leontieva & Blagosklonny, 2013).  
A study by Bontempo et al. (2009) in human acute promyelocytic leukemia (NB4) cells had 
reported an increase in p16 and p21 protein expression levels when cells were treated with 
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BPA. The study noted unchanged p53 protein levels. On the same lines, a study by Qin et al. 
(2012) in human mammary epithelial cells (HMEC) had also reported an increase in p16 
protein levels when cells were exposed to BPA inducing cellular senescence. However, the 
study showed no significant increase in p53 protein levels which was contrary to our result, 
wherein p53 protein levels showed marked increase compared to the control. The difference 
in the results might be due to the difference in dose and cell models utilized in the studies. 
Increased p16 protein levels in BPA compared to control was similar to the study by Qin et 
al. (2012). But there was no change observed in p21 protein levels in the presence of BPA 
(Figure 3). This confirms that BPA along with metabolic stress may induce cellular 
senescence through p15/p16-Rb1 axis independent of p53 pathway. In addition to this, there 
was a possibility of apoptosis happening when tissues get exposed to BPA. This was inferred 
from the significant increase in p53 protein levels and unaltered p21 protein levels in BPA 
treated. This result was consistent with our in vivo experiment (Chapter 3). Our study is the 
first to show the presence of senescence and its pathway, when BPA combines with 
metabolic stress condition.  
In addition to these, our study measured the levels of glucose uptake in skeletal muscle cells 
to understand the impact of BPA on glucose metabolism. Skeletal muscle is the major site for 
insulin-mediated glucose uptake (DeFronzo & Tripathy, 2009). GLUT-4 is the major glucose 
transporter expressed in skeletal muscle cells which aids in glucose uptake (Zorzano et al., 
2005). Reduction in GLUT-4 expression in the skeletal muscle cells is a characteristic feature 
of patients with type 2 diabetes, resulting in the reduced capability to process glucose (Maier 
& Gould, 2000).  
Previous studies have reported a detrimental effect of BPA on glucose uptake and GLUT-4 
expression in animal models. A study by Indumathi et al. (2013) in wister rats had reported a 
significant reduction in the GLUT-4 expression levels in skeletal muscle cells when rats were 
administered with BPA. The study concluded that BPA has drastic effect on GLUT-4 
translocation. A recent study by Mullainadhan et al. (2017) had also demonstrated a 
significant decrease in GLUT-4 expression and insulin-stimulated glucose uptake in male 
albino rats after the animals were exposed to BPA. However, there is a dearth of 
understanding on the extent to which BPA affects the GLUT-4 translocation when it adds up 
to the metabolic stress condition. Our study focused on this aspect.  
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Insulin-stimulated glucose uptake was measured in skeletal muscles by 2-(N-(7-Nitrobenz-2-
oxa-1,3-diazol-4-yl)Amino)-2-Deoxyglucose (2-NBDG) assay. 2-NBDG is a reliable marker 
to identify the levels of insulin-stimulated glucose uptake (Chen et al.,2015). The results 
obtained in our study were in accordance with the results reported by Indumathi et al. (2013) 
and Mullainadhan et al. (2017). Both the treatments involving BPA (BPA alone and 
combination treatment) showed significant reduction in the levels of insulin-stimulated 
glucose uptake in skeletal muscle cells (Figure 4). However, there was no significant change 
between BPA alone and combination of BPA and high glucose condition. This indicates that 
BPA on its own or in combination with metabolic stress produces the same level of 
effectiveness on the process of glucose uptake. Further studies are required on this direction 
on the effectiveness of BPA under the influence of metabolic stress on glucose uptake with 
different concentrations of BPA.  
Protein analysis through western blot indicated a decreasing trend in GLUT-4 protein in BPA 
treated and a significant decrease in BPA and high glucose combination treatment compared 
to control (Figure 5). C2C12 cells treated with BPA showed significantly reduced glucose 
uptake, albeit with only a decreased trend of GLUT-4 protein expression. This could be due 
to post-translational modifications (PTMs) linked to biological activity such as glucose 
uptake (Sadlier et al., 2013). Deterioration of GLUT-4 expression will result in impaired 
insulin-stimulated glucose uptake in the skeletal muscle cells, which is commonly seen in 
T2DM patients (Stanford & Goodyear, 2014). Our study for the first time showed that BPA 
under the influence of metabolic stress condition will diminish the GLUT-4 expression. 
Future studies must focus on the effect of BPA on glucose metabolism under the influence of 
metabolic stress conditions in animal models.   
In conclusion, our study demonstrated that BPA under the influence of metabolic stress can 
dysregulate glucose metabolism affecting the glucose uptake in a metabolic tissue such as 
skeletal muscle through mechanism of increased senescence.  
 
 
 
 
 97 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
Nut-shell Findings and Future Directions  
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While several epidemiological studies have suggested that BPA exposure is positively 
associated with an increased risk of T2DM (Sowlat et al., 2016; Provvisiero et al., 2016; 
Chailurkit et al., 2017), there is lack of data on this in Asian Indians, a population highly 
prone to the epidemic of diabetes and its vascular complications (Gujral et al., 2015). To 
fulfil this important and contemporary research gap, this study for the first-time, unravelled 
the link between BPA and T2DM in a holistic way utilizing the clinical samples, in vivo 
animal model and in vitro skeletal muscle cell model based biochemical and molecular 
investigations. 
Our clinical study revealed that serum levels of BPA were significantly higher in patients 
with T2DM compared to control individuals. BPA levels in T2DM subjects were also 
positively correlated to poor glycemic control and insulin resistance. Gene expression 
analysis in PBMCs revealed that patients with T2DM exhibited significantly elevated mRNA 
levels of senescence (GLB1, p16, p21 and p53) and inflammatory (IL6 and TNF-α) markers. 
The chronic burden of senescence and inflammation was also reflected by significantly 
reduced and shortened telomeres in patients with T2DM compared to control subjects. 
Interestingly, PBMCs from patients with T2DM also exhibited significantly elevated mRNA 
expression of ERRγ, a recently identified receptor for BPA. This study is the first to 
demonstrate an association of increased BPA levels with cellular senescence, pro-
inflammation, poor glycemic control, insulin resistance and shortened telomeres in patients 
with T2DM. 
Our clinical study sets the tone for rest of the studies where in causative mechanism of BPA 
action in the pathogenesis of T2DM was studied in detail through in vivo (zebrafish) and in 
vitro (skeletal muscle cell) studies.  
In order to better understand the causal mechanisms of BPA, zebrafish embryos were treated 
with BPA in the absence and presence of metabolic stress (hyperglycaemia) condition. 
Interestingly, the increase in glucose levels seen in zebrafish embryos under hyperglycaemia 
was significantly augmented in the presence of BPA. Transcriptional levels of senescence 
markers such as p15, p53, Rb1 and β-galactosidase (β-gal) were increased in combination of 
metabolic stress and BPA exposure, and this was also supported by β-gal enzyme expression 
patterns. In addition, embryos exposed to hyperglycaemia and BPA also exhibited increased 
apoptosis as evident from acridine orange and cleaved caspase-3 antibody staining. The fact 
that senescent markers were elevated even in p53 knockdown conditions suggests that 
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senescence might majorly involve p15-Rb1 pathway when embryos were treated with 
metabolic stress coupled to BPA exposure. Our work exposes a novel and unique converging 
role of senescence and apoptosis axis contributing to glucose dyshomeostasis. 
Interestingly, our study revealed that senescence happens simultaneously with apoptosis. In 
general, senescent cell activates several pro-survival genes thus becoming resistant to 
apoptosis (Zhu et al., 2015). However, we showed that both senescence and apoptosis occur 
simultaneously. It has to be seen further whether BPA induces ectopic expression of p16 
induced p53 mediated apoptosis, as this was reported to be happening in different cancer cells 
(Katsuda et al., 2002; Tamm et al., 2002). 
When analysed the effects of BPA under the influence of metabolic stress (hyperglycemia) in 
a metabolic tissue like skeletal muscle, our results reconfirmed the presence of accelerated 
senescence that is mediated through p16-Rb1 axis. Skeletal muscle cells exposed to glycemic 
excursions showed impaired glucose transporter expression as well as decreased glucose 
uptake and this was significantly augmented in the presence of BPA. 
One of the limitations of our study is of its cross-sectional nature and the causal link between 
elevated systemic levels of BPA and T2DM needs to be further investigated in a prospective 
follow-up study. 
While our clinical study supports the acquisition of Senescence Associated Secretary 
phenotype (SASP) nature of cells and tissues in patients with T2DM, the underlying 
molecular signatures and mechanisms needs to be studied in model organisms and in vitro 
studies with much more focus.  
While Asian Indians are suffering from T2DM at an early age compared to others, the 
concept of accelerated aging and related pathways has become a thrust area of research for 
both prevention as well as management of metabolic disorders including T2DM. In this 
direction, the present study is considered as a significant research contribution. 
While the prevalence of gestational diabetes is increasing worldwide contributing to the 
escalating epidemic of T2DM in women, recent studies have already imposed a ‘cause for 
concern’ on the genesis of gestational diabetes that could originate from the exposure to 
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EDCs like BPA. Therefore, future in-depth studies are warranted to dissect out the 
mechanisms and prevention strategies. 
With important findings and futuristic avenues, this study helped us to understand the impact 
of environmental contaminants like BPA on the pathogenesis of diabetes. By acquiring in-
depth knowledge on this we hope in future, targeted therapies can be improved upon by 
avoiding these confounding external factors that may form an impediment in treatment. 
The Strategic Approach to International Chemicals Management (SAICM) considers EDCs 
as an "emerging policy issue". While many countries take actions to mitigate their dangers, 
the issue is not in the public domain in India, and there is very little information and data 
available. Thus, with better knowledge and understanding of these environmental pollutants 
and toxicants, we can look forward for appropriate national and international policies and 
laws to regulate the usage of endocrine disruptor chemicals like BPA. 
Future is full of hopes! 
Plastic free….. BPA-free….. and Free of Diabetes and other Metabolic Disorders….. 
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